<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
      <restricted-by>pmc</restricted-by>
    </processing-meta>
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Blood Adv</journal-id>
        <journal-id journal-id-type="iso-abbrev">Blood Adv</journal-id>
        <journal-id journal-id-type="pmc-domain-id">3318</journal-id>
        <journal-id journal-id-type="pmc-domain">bloodadv</journal-id>
        <journal-title-group>
          <journal-title>Blood Advances</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">2473-9529</issn>
        <issn pub-type="epub">2473-9537</issn>
        <publisher>
          <publisher-name>The American Society of Hematology</publisher-name>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC10480533</article-id>
        <article-id pub-id-type="pmcid-ver">PMC10480533.1</article-id>
        <article-id pub-id-type="pmcaid">10480533</article-id>
        <article-id pub-id-type="pmcaiid">10480533</article-id>
        <article-id pub-id-type="pmid">37078708</article-id>
        <article-id pub-id-type="doi">10.1182/bloodadvances.2023009953</article-id>
        <article-id pub-id-type="pii">S2473-9529(23)00212-4</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Lymphoid Neoplasia</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title><italic toggle="yes">TP53</italic> mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author" id="au1">
            <name name-style="western">
              <surname>Johnson</surname>
              <given-names initials="WT">William T.</given-names>
            </name>
            <email>johnsow3@mskcc.org</email>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
            <xref rid="cor1" ref-type="corresp">âˆ—</xref>
          </contrib>
          <contrib contrib-type="author" id="au2">
            <name name-style="western">
              <surname>Ganesan</surname>
              <given-names initials="N">Nivetha</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author" id="au3">
            <name name-style="western">
              <surname>Epstein-Peterson</surname>
              <given-names initials="ZD">Zachary D.</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au4">
            <name name-style="western">
              <surname>Moskowitz</surname>
              <given-names initials="AJ">Alison J.</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au5">
            <name name-style="western">
              <surname>Stuver</surname>
              <given-names initials="RN">Robert N.</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author" id="au6">
            <name name-style="western">
              <surname>Maccaro</surname>
              <given-names initials="CR">Catherine R.</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author" id="au7">
            <name name-style="western">
              <surname>Galasso</surname>
              <given-names initials="N">Natasha</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author" id="au8">
            <name name-style="western">
              <surname>Chang</surname>
              <given-names initials="T">Tiffany</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author" id="au9">
            <name name-style="western">
              <surname>Khan</surname>
              <given-names initials="N">Niloufer</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au10">
            <name name-style="western">
              <surname>Aypar</surname>
              <given-names initials="U">Umut</given-names>
            </name>
            <xref rid="aff3" ref-type="aff">3</xref>
          </contrib>
          <contrib contrib-type="author" id="au11">
            <name name-style="western">
              <surname>Lewis</surname>
              <given-names initials="NE">Natasha E.</given-names>
            </name>
            <xref rid="aff4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author" id="au12">
            <name name-style="western">
              <surname>Zelenetz</surname>
              <given-names initials="AD">Andrew D.</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au13">
            <name name-style="western">
              <surname>Palomba</surname>
              <given-names initials="ML">M. Lia</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au14">
            <name name-style="western">
              <surname>Matasar</surname>
              <given-names initials="MJ">Matthew J.</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au15">
            <name name-style="western">
              <surname>Noy</surname>
              <given-names initials="A">Ariela</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au16">
            <name name-style="western">
              <surname>Hamilton</surname>
              <given-names initials="AM">Audrey M.</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au17">
            <name name-style="western">
              <surname>Hamlin</surname>
              <given-names initials="P">Paul</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au18">
            <name name-style="western">
              <surname>Caron</surname>
              <given-names initials="PC">Philip C.</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au19">
            <name name-style="western">
              <surname>Straus</surname>
              <given-names initials="DJ">David J.</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au20">
            <name name-style="western">
              <surname>Intlekofer</surname>
              <given-names initials="AM">Andrew M.</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
            <xref rid="aff5" ref-type="aff">5</xref>
          </contrib>
          <contrib contrib-type="author" id="au21">
            <name name-style="western">
              <surname>Lee Batlevi</surname>
              <given-names initials="C">Connie</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au22">
            <name name-style="western">
              <surname>Kumar</surname>
              <given-names initials="A">Anita</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au23">
            <name name-style="western">
              <surname>Owens</surname>
              <given-names initials="CN">Colette N.</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au24">
            <name name-style="western">
              <surname>Sauter</surname>
              <given-names initials="CS">Craig S.</given-names>
            </name>
            <xref rid="aff6" ref-type="aff">6</xref>
          </contrib>
          <contrib contrib-type="author" id="au25">
            <name name-style="western">
              <surname>Falchi</surname>
              <given-names initials="L">Lorenzo</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au26">
            <name name-style="western">
              <surname>Lue</surname>
              <given-names initials="JK">Jennifer K.</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au27">
            <name name-style="western">
              <surname>Vardhana</surname>
              <given-names initials="SA">Santosha A.</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
            <xref rid="aff5" ref-type="aff">5</xref>
          </contrib>
          <contrib contrib-type="author" id="au28">
            <name name-style="western">
              <surname>Salles</surname>
              <given-names initials="G">Gilles</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author" id="au29">
            <name name-style="western">
              <surname>Dogan</surname>
              <given-names initials="A">Ahmet</given-names>
            </name>
            <xref rid="aff4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author" id="au30">
            <name name-style="western">
              <surname>Schultz</surname>
              <given-names initials="ND">Nikolaus D.</given-names>
            </name>
            <xref rid="aff7" ref-type="aff">7</xref>
          </contrib>
          <contrib contrib-type="author" id="au31">
            <name name-style="western">
              <surname>Arcila</surname>
              <given-names initials="ME">Maria E.</given-names>
            </name>
            <xref rid="aff8" ref-type="aff">8</xref>
          </contrib>
          <contrib contrib-type="author" id="au32">
            <name name-style="western">
              <surname>Horwitz</surname>
              <given-names initials="SM">Steven M.</given-names>
            </name>
            <xref rid="aff1" ref-type="aff">1</xref>
            <xref rid="aff2" ref-type="aff">2</xref>
          </contrib>
          <aff id="aff1"><label>1</label>Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
          <aff id="aff2"><label>2</label>Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY</aff>
          <aff id="aff3"><label>3</label>Department of Pathology, Cytogenetics Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
          <aff id="aff4"><label>4</label>Department of Pathology, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
          <aff id="aff5"><label>5</label>Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
          <aff id="aff6"><label>6</label>Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH</aff>
          <aff id="aff7"><label>7</label>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
          <aff id="aff8"><label>8</label>Department of Pathology, Molecular Diagnostic Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        </contrib-group>
        <author-notes>
          <corresp id="cor1"><label>âˆ—</label>Correspondence: William T. Johnson, Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, 530 East 74th St, New York, NY 10021; <email>johnsow3@mskcc.org</email></corresp>
        </author-notes>
        <pub-date pub-type="collection">
          <day>12</day>
          <month>9</month>
          <year>2023</year>
        </pub-date>
        <pub-date pub-type="epub">
          <day>25</day>
          <month>4</month>
          <year>2023</year>
        </pub-date>
        <volume>7</volume>
        <issue>17</issue>
        <issue-id pub-id-type="pmc-issue-id">444210</issue-id>
        <fpage>5172</fpage>
        <lpage>5186</lpage>
        <history>
          <date date-type="received">
            <day>7</day>
            <month>2</month>
            <year>2023</year>
          </date>
          <date date-type="accepted">
            <day>25</day>
            <month>3</month>
            <year>2023</year>
          </date>
        </history>
        <pub-history>
          <event event-type="pmc-release">
            <date>
              <day>25</day>
              <month>04</month>
              <year>2023</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>07</day>
              <month>09</month>
              <year>2023</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2023-09-07 03:25:31.520">
              <day>07</day>
              <month>09</month>
              <year>2023</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>Â© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.</copyright-statement>
          <copyright-year>2023</copyright-year>
          <copyright-holder>The American Society of Hematology</copyright-holder>
          <license>
            <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
            <license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
          </license>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/>
        <abstract abstract-type="author-highlights" id="abs0010">
          <title>Key Points</title>
          <p>
            <list list-type="simple" id="ulist0010">
              <list-item id="u0010">
                <label>â€¢</label>
                <p id="p0010"><italic toggle="yes">TP53</italic> mutations are frequent events in certain subtypes of PTCL.</p>
              </list-item>
              <list-item id="u0015">
                <label>â€¢</label>
                <p id="p0015">Patients with <italic toggle="yes">TP53</italic>-mutated PTCL experience high relapse rates when treated with curative-intent CHOP-based chemotherapy.</p>
              </list-item>
            </list>
          </p>
        </abstract>
        <abstract abstract-type="graphical" id="abs0015">
          <title>Visual Abstract</title>
          <fig id="undfig1" position="anchor" orientation="portrait">
            <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BLOODA_ADV-2023-009953-fx1.jpg"/>
          </fig>
        </abstract>
        <abstract id="abs0020">
          <title>Abstract</title>
          <p>Nodal peripheral T-cell lymphomas (PTCL), the most common PTCLs, are generally treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based curative-intent chemotherapy. Recent molecular data have assisted in prognosticating these PTCLs, but most reports lack detailed baseline clinical characteristics and treatment courses. We retrospectively evaluated cases of PTCL treated with CHOP-based chemotherapy that had tumors sequenced by the Memorial Sloan Kettering Integrated Mutational Profiling of Actionable Cancer Targets next-generation sequencing panel to identify variables correlating with inferior survival. We identified 132 patients who met these criteria. Clinical factors correlating with an increased risk of progression (by multivariate analysis) included advanced-stage disease and bone marrow involvement. The only somatic genetic aberrancies correlating with inferior progression-free survival (PFS) were <italic toggle="yes">TP53</italic> mutations and <italic toggle="yes">TP53/</italic>17p deletions. PFS remained inferior when stratifying by <italic toggle="yes">TP53</italic> mutation status, with a median PFS of 4.5Â months for PTCL with a <italic toggle="yes">TP53</italic> mutation (nÂ = 21) vs 10.5Â months for PTCL without a <italic toggle="yes">TP53</italic> mutation (nÂ = 111). No <italic toggle="yes">TP53</italic> aberrancy correlated with inferior overall survival (OS). Although rare (nÂ = 9), <italic toggle="yes">CDKN2A</italic>-deleted PTCL correlated with inferior OS, withÂ a median of 17.6Â months vs 56.7Â months for patients without <italic toggle="yes">CDKN2A</italic> deletions. This retrospective study suggests that patients with PTCL with <italic toggle="yes">TP53</italic> mutations experience inferior PFS when treated with curative-intent chemotherapy, warranting prospective confirmation.</p>
        </abstract>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <sec id="sec1">
        <title>Introduction</title>
        <p id="p0020">Comprising âˆ¼10% to 15% of all non-Hodgkin lymphoma cases, peripheral T-cell lymphoma (PTCL) encompasses more than 30 histological subtypes.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> The relative frequency of each subtype is influenced by geographic region, but the most common PTCL, globally, remains nodal PTCL.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Nodal PTCLs include PTCLâ€“not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), other PTCL with a follicular T-helper cell phenotype (PTCL-TFH), and anaplastic large cell lymphoma (ALCL), including anaplastic lymphoma kinase (ALK)-positive and -negative disease.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref> Although pathologically and molecularly distinct, nodal PTCLs are most often treated similarly, with curative-intent cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based chemotherapy for eligible patients.<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref> In patients with CD30<sup>+</sup> PTCL, vincristine can be replaced by brentuximab vedotin (BV), based on the ECHELON-2 data showing improved survival compared with use of CHOP, although this advantage was predominantly driven by patients with ALCL.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> For those with CD30<sup>â€“</sup> PTCL, etoposide can be added, which has been correlated with improved response rates and survival, particularly in patients aged â‰¤60 years.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> For eligible patients who achieve remission, high-dose chemotherapy with autologous stem cell transplantation (ASCT) rescue can be offered, with ASCT showing a survival advantage in nonrandomized prospective trials, compared with historical control therapies, and in some retrospective analyses.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref></p>
        <p id="p0025">Over the past decade, the genetic landscape and oncogenic underpinning of PTCL have been more clearly delineated and, to some extent, can aid in prognosticating and predicting the response to treatments.<xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref> However, although most studies define molecular risk factors for inferior overall survival (OS), they often omit comprehensive details on both first-line treatment and treatment at relapse. Moreover, few reports detail somatic genetic risk factors for refractory or relapsed disease when treated with curative-intent strategies. This makes it challenging to risk stratify patients who may benefit from alternative induction and consolidation strategies and to stratify patients in future first-line randomized control trials.</p>
        <p id="p0030">We sought to add to the existing PTCL genetic literature by incorporating baseline clinical characteristics and comprehensive treatment data for a cohort of patients treated with curative-intent CHOP-based chemotherapy and to combine these data with a clinically validated targeted next-generation sequencing (NGS) panel to identify features of patients at highest risk for relapsed or refractory disease.</p>
      </sec>
      <sec id="sec2">
        <title>Methods</title>
        <sec id="sec2.1">
          <title>Patient selection</title>
          <p id="p0035">The protocol for this retrospective study was approved by the institutional review board (IRB) at Memorial Sloan Kettering Cancer Center (MSK; IRB #22-025) and was written in compliance with the principles outlined in the Declaration of Helsinki. The online platform cBioPortal for Cancer Genomics was used to screen for all patients with PTCL who visited MSK from 1 April 2015 to 31 December 2020 and had NGS of tumor biopsies performed primarily via the Memorial Sloan Kettering Cancer Center Integrated Mutational Profiling of Actionable Cancer Targets (MSK-IMPACT; 1 included tumor was sequenced using a smaller 49-gene MSK-targeted sequencing panel at diagnosis).<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> MSK-IMPACT is a clinically validated, targeted NGS panel analyzing somatic alterations in up to 500 genes.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> Using various iterations of this NGS platform, the mutational landscape of &gt;10Â 000 tumors has been published, and MSK-IMPACT has become an integral part of the PTCL pathological work-up at MSK.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref></p>
          <p id="p0040">MSK-IMPACT panels and sequencing results are provided in <xref rid="appsec1" ref-type="sec">supplemental TableÂ 1</xref>. In addition to the nodal PTCL subtypes, we also included enteropathy-associated T-cell lymphoma and monomorphic epitheliotropic T-cell lymphoma (MEITL) because they are treated similarly to nodal PTCL.</p>
          <p id="p0045">Subsequently, patientsâ€™ electronic medical records were manually reviewed to confirm the diagnosis and first-line treatment regimen (regimens listed in <xref rid="tbl1" ref-type="table">TableÂ 1</xref>). All diagnoses were confirmed by â‰¥1 hematopathologist at MSK. We included only adults aged â‰¥18 years. Patients were excluded if they were lost to follow-up during first-line treatment, underwent allogeneic stem cell transplantation (allo-SCT) in first remission, or had active central nervous system involvement at the time of diagnosis. We manually extracted electronic medical records data on baseline clinical characteristics, treatments, and survival for patients meeting all inclusion criteria, which included having an aforementioned histology, being treated with curative-intent CHOP-based chemotherapy (with or without ASCT in first remission), and having MSK-IMPACT performed on biopsied tumor tissue.<table-wrap position="float" id="tbl1" orientation="portrait"><label>TableÂ 1.</label><caption><p><bold>Baseline clinical characteristics and treatments of the 3 PTCL cohorts</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1">Entire cohort (NÂ = 132)</th><th colspan="1" rowspan="1">CCD cohort (nÂ = 87)</th><th colspan="1" rowspan="1">Prospective cohort (nÂ = 72)</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th></tr></thead><tbody><tr><td colspan="5" rowspan="1"><bold>Demographics</bold></td></tr><tr><td colspan="1" rowspan="1">Â Median age, y (range)</td><td align="char" colspan="1" rowspan="1">65 (25-82)</td><td align="char" colspan="1" rowspan="1">63 (26-81)</td><td align="char" colspan="1" rowspan="1">66 (25-81)</td><td align="char" colspan="1" rowspan="1">.87</td></tr><tr><td colspan="1" rowspan="1">Â Male, n (%)</td><td align="char" colspan="1" rowspan="1">81 (61)</td><td align="char" colspan="1" rowspan="1">56 (64)</td><td align="char" colspan="1" rowspan="1">43 (60)</td><td align="char" colspan="1" rowspan="1">.83</td></tr><tr><td colspan="5" rowspan="1"><bold>Disease characteristics at diagnosis</bold></td></tr><tr><td colspan="1" rowspan="1">Â Histology, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â PTCL-NOS</td><td align="char" colspan="1" rowspan="1">36 (27)</td><td align="char" colspan="1" rowspan="1">28 (32)</td><td align="char" colspan="1" rowspan="1">15 (21)</td><td align="char" colspan="1" rowspan="1">.25</td></tr><tr><td colspan="1" rowspan="1">Â AITL</td><td align="char" colspan="1" rowspan="1">62 (47)</td><td align="char" colspan="1" rowspan="1">39 (45)</td><td align="char" colspan="1" rowspan="1">38 (53)</td><td align="char" colspan="1" rowspan="1">.59</td></tr><tr><td colspan="1" rowspan="1">Â PTCL-TFH</td><td align="char" colspan="1" rowspan="1">9 (7)</td><td align="char" colspan="1" rowspan="1">6 (7)</td><td align="char" colspan="1" rowspan="1">6 (8)</td><td align="char" colspan="1" rowspan="1">.92</td></tr><tr><td colspan="1" rowspan="1">Â ALK<sup>âˆ’</sup> ALCL</td><td align="char" colspan="1" rowspan="1">15 (11)</td><td align="char" colspan="1" rowspan="1">8 (9)</td><td align="char" colspan="1" rowspan="1">7 (10)</td><td align="char" colspan="1" rowspan="1">.88</td></tr><tr><td colspan="1" rowspan="1">Â ALK<sup>+</sup> ALCL</td><td align="char" colspan="1" rowspan="1">6 (5)</td><td align="char" colspan="1" rowspan="1">2 (2)</td><td align="char" colspan="1" rowspan="1">2 (3)</td><td align="char" colspan="1" rowspan="1">.71</td></tr><tr><td colspan="1" rowspan="1">Â MEITL</td><td align="char" colspan="1" rowspan="1">4 (3)</td><td align="char" colspan="1" rowspan="1">4 (5)</td><td align="char" colspan="1" rowspan="1">4 (6)</td><td align="char" colspan="1" rowspan="1">.65</td></tr><tr><td colspan="1" rowspan="1">Â Stage, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â I/II<xref rid="tbl1fnlowast" ref-type="table-fn">âˆ—</xref></td><td align="char" colspan="1" rowspan="1">22 (17)</td><td align="char" colspan="1" rowspan="1">15 (17)</td><td align="char" colspan="1" rowspan="1">14 (19)</td><td align="char" colspan="1" rowspan="1">.90</td></tr><tr><td colspan="1" rowspan="1">Â III/IV<xref rid="tbl1fnlowast" ref-type="table-fn">âˆ—</xref></td><td align="char" colspan="1" rowspan="1">110 (83)</td><td align="char" colspan="1" rowspan="1">72 (83)</td><td align="char" colspan="1" rowspan="1">58 (81)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â BM involvement by morphological assessment, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â No</td><td align="char" colspan="1" rowspan="1">72 (55)</td><td align="char" colspan="1" rowspan="1">55 (63)</td><td align="char" colspan="1" rowspan="1">42 (58)</td><td align="char" colspan="1" rowspan="1">.99</td></tr><tr><td colspan="1" rowspan="1">Â Yes</td><td align="char" colspan="1" rowspan="1">39 (29)</td><td align="char" colspan="1" rowspan="1">32 (37)</td><td align="char" colspan="1" rowspan="1">23 (32)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â Unknown</td><td align="char" colspan="1" rowspan="1">21 (16)</td><td align="char" colspan="1" rowspan="1">0 (0)</td><td align="char" colspan="1" rowspan="1">7 (10)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â Extranodal disease other than BM involvement,Â nÂ (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â No</td><td align="char" colspan="1" rowspan="1">81 (61)</td><td align="char" colspan="1" rowspan="1">52 (60)</td><td align="char" colspan="1" rowspan="1">44 (61)</td><td align="char" colspan="1" rowspan="1">.98</td></tr><tr><td colspan="1" rowspan="1">Â Yes</td><td align="char" colspan="1" rowspan="1">51 (39)</td><td align="char" colspan="1" rowspan="1">35 (40)</td><td align="char" colspan="1" rowspan="1">28 (39)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â LDH elevated, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â No</td><td align="char" colspan="1" rowspan="1">39 (30)</td><td align="char" colspan="1" rowspan="1">34 (39)</td><td align="char" colspan="1" rowspan="1">29 (40)</td><td align="char" colspan="1" rowspan="1">.91</td></tr><tr><td colspan="1" rowspan="1">Â Yes</td><td align="char" colspan="1" rowspan="1">58 (44)</td><td align="char" colspan="1" rowspan="1">53 (61)</td><td align="char" colspan="1" rowspan="1">39 (54)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â Unknown</td><td align="char" colspan="1" rowspan="1">35 (27)</td><td align="char" colspan="1" rowspan="1">0 (0)</td><td align="char" colspan="1" rowspan="1">4 (6)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â ECOG PS â‰¥2, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â No</td><td align="char" colspan="1" rowspan="1">112 (85)</td><td align="char" colspan="1" rowspan="1">77 (89)</td><td align="char" colspan="1" rowspan="1">62 (86)</td><td align="char" colspan="1" rowspan="1">.87</td></tr><tr><td colspan="1" rowspan="1">Â Yes</td><td align="char" colspan="1" rowspan="1">14 (11)</td><td align="char" colspan="1" rowspan="1">10 (11)</td><td align="char" colspan="1" rowspan="1">10 (14)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â Unknown</td><td align="char" colspan="1" rowspan="1">6 (5)</td><td align="char" colspan="1" rowspan="1">0 (0)</td><td align="char" colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â IPI score, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â 0-1</td><td align="char" colspan="1" rowspan="1">18 (14)</td><td align="char" colspan="1" rowspan="1">17 (20)</td><td align="char" colspan="1" rowspan="1">14 (19)</td><td align="char" colspan="1" rowspan="1">.99</td></tr><tr><td colspan="1" rowspan="1">Â 2</td><td align="char" colspan="1" rowspan="1">30 (23)</td><td align="char" colspan="1" rowspan="1">28 (32)</td><td align="char" colspan="1" rowspan="1">22 (31)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â 3</td><td align="char" colspan="1" rowspan="1">31 (24)</td><td align="char" colspan="1" rowspan="1">31 (36)</td><td align="char" colspan="1" rowspan="1">20 (28)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â 4-5</td><td align="char" colspan="1" rowspan="1">15 (11)</td><td align="char" colspan="1" rowspan="1">11 (14)</td><td align="char" colspan="1" rowspan="1">11 (15)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â Incomplete data</td><td align="char" colspan="1" rowspan="1">38 (29)</td><td align="char" colspan="1" rowspan="1">0 (0)</td><td align="char" colspan="1" rowspan="1">5 (7)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â PIT score, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â 0-1</td><td align="char" colspan="1" rowspan="1">44 (33)</td><td align="char" colspan="1" rowspan="1">44 (51)</td><td align="char" colspan="1" rowspan="1">30 (42)</td><td align="char" colspan="1" rowspan="1">.95</td></tr><tr><td colspan="1" rowspan="1">Â 2</td><td align="char" colspan="1" rowspan="1">24 (18)</td><td align="char" colspan="1" rowspan="1">24 (28)</td><td align="char" colspan="1" rowspan="1">20 (28)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â 3-4</td><td align="char" colspan="1" rowspan="1">19 (14)</td><td align="char" colspan="1" rowspan="1">19 (22)</td><td align="char" colspan="1" rowspan="1">11 (15)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â Incomplete data</td><td align="char" colspan="1" rowspan="1">45 (34)</td><td align="char" colspan="1" rowspan="1">0 (0)</td><td align="char" colspan="1" rowspan="1">11 (15)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Treatments</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â Chemotherapy regimen, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â CHOEP/EPOCH</td><td align="char" colspan="1" rowspan="1">59 (45)</td><td align="char" colspan="1" rowspan="1">38 (44)</td><td align="char" colspan="1" rowspan="1">31 (43)</td><td align="char" colspan="1" rowspan="1">.97</td></tr><tr><td colspan="1" rowspan="1">Â CHOP</td><td align="char" colspan="1" rowspan="1">40 (30)</td><td align="char" colspan="1" rowspan="1">23 (26)</td><td align="char" colspan="1" rowspan="1">19 (26)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â BV-CH(E)P</td><td align="char" colspan="1" rowspan="1">16 (12)</td><td align="char" colspan="1" rowspan="1">12 (14)</td><td align="char" colspan="1" rowspan="1">11 (15)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â CHOP-basedÂ + novel agent</td><td align="char" colspan="1" rowspan="1">17 (13)</td><td align="char" colspan="1" rowspan="1">14 (16)</td><td align="char" colspan="1" rowspan="1">11 (15)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â ASCT in first remission, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â No</td><td align="char" colspan="1" rowspan="1">82 (62)</td><td align="char" colspan="1" rowspan="1">50 (57)</td><td align="char" colspan="1" rowspan="1">39 (54)</td><td align="char" colspan="1" rowspan="1">.52</td></tr><tr><td colspan="1" rowspan="1">Â Yes</td><td align="char" colspan="1" rowspan="1">50 (38)</td><td align="char" colspan="1" rowspan="1">37 (43)</td><td align="char" colspan="1" rowspan="1">33 (46)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Maintenance therapy, n (%)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â No</td><td align="char" colspan="1" rowspan="1">119 (90)</td><td align="char" colspan="1" rowspan="1">75 (86)</td><td align="char" colspan="1" rowspan="1">60 (83)</td><td align="char" colspan="1" rowspan="1">.34</td></tr><tr><td colspan="1" rowspan="1">Â Yes</td><td align="char" colspan="1" rowspan="1">13 (10)</td><td align="char" colspan="1" rowspan="1">12 (14)</td><td align="char" colspan="1" rowspan="1">12 (17)</td><td colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>BV-CH(E)P, CHOP with brentuximab vedotin in place of vincristine with or without etoposide; CHOEP, CHOP with etoposide; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnlowast"><label>âˆ—</label><p id="ntpara0025">One patient with documented stage II disease and 8 patients with documented stage III disease based on imaging were missing baseline BM biopsies.</p></fn></table-wrap-foot></table-wrap></p>
          <p id="p0050">We anticipated that some patients with tumors sequenced via MSK-IMPACT were not patients of an MSK oncologist during first-line therapy, thus, potentially missing key clinical baseline prognostic data, and/or patients for whom MSK-IMPACT would have had been ordered only at the time of relapse, thereby inducing a selection bias. Accordingly, 3 cohorts were grouped for analysis: (1) the entire MSK-IMPACTâ€“sequenced cohort meeting the inclusion criteria (entire cohort); (2) a cohort with complete clinical baseline prognostic data, including pretreatment laboratory data and baseline bone marrow (BM) biopsies (complete clinical data [CCD] cohort); and (3) the cohort that was managed by an MSK oncologist during the CHOP-based treatment and also had their pretreatment tumor biopsy sequenced at the time of CHOP-based treatment and/or before relapse, when applicable (prospective cohort).</p>
          <p id="p0055">MSK-IMPACT results from pretreatment biopsies were analyzed when available; sequencing results from progression biopsies (applicable only to the entire and CCD cohorts) were otherwise analyzed.</p>
        </sec>
        <sec id="sec2.2">
          <title>Statistical analysis</title>
          <p id="p0060">Progression-free survival (PFS) was calculated from the start of chemotherapy to progression or death. The OS was calculated from the start chemotherapy to the date of death, with data of living patients censored at the time of the last documented follow-up, with a data cutoff on 31 MayÂ 2021.</p>
          <p id="p0065">Univariate analysis was performed using a Cox proportional hazards regression analysis for PFS and OS. Characteristics with <italic toggle="yes">P</italic> â‰¤ .05 in the univariate analyses were included in a multivariate analysis. Baseline clinical parameters were chosen based on previously described prognostic indicators in PTCL.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> Characteristics also included the use of etoposide, use of BV, receipt of consolidation ASCT in first remission, and/or receipt of maintenance therapy after CHOP-based chemotherapy with or without consolidative ASCT. Further characteristics included genetic aberrancies (mutations or copy number alterations [CNAs]) that occurred in â‰¥5% of the entire cohort.</p>
          <p id="p0070">Fisher's exact test and the Wilcoxon rank sum test were used for the descriptive statistical analyses of categorical data and continuous data, respectively. Comparisons between survival curves were performed using the log-rank test, and hazard ratios (HRs) were computed using the Cox proportional hazards model. Data analysis was generated using SAS software (Cary, NC). The oncoplot was developed using R and Complex Heatmap package (version 4.2.2), and the lollipop plot was generated using cBioPortal.</p>
        </sec>
      </sec>
      <sec id="sec3">
        <title>Results</title>
        <sec id="sec3.1">
          <title>Patient distribution into cohorts</title>
          <p id="p0075">A total of 396 patients with PTCL sequenced via MSK-IMPACT were identified through cBioPortal, of whom 179 (45%) had a confirmed histology of interest. Of these 179 patients, 141 (79%) were treated with a CHOP-based regimen. Nine patients were further excluded, leaving 132 patients comprising the entire cohort (<xref rid="fig1" ref-type="fig">FigureÂ 1</xref>). There were 45 patients (34%) missing â‰¥1 baseline clinical prognostic parameter (<xref rid="tbl1" ref-type="table">TableÂ 1</xref>). Missing baseline clinical variables included lactate dehydrogenase level (LDH), the most frequent and only missing variable in 24 patients (18%), followed by BM biopsies, the only missing variable in 10 patients (8%); both baseline LDH and BM biopsies were missing in 11 patients (8%). Thus, the CCD cohort consisted of 87 patients (66%; <xref rid="fig1" ref-type="fig">FigureÂ 1</xref>).<fig id="fig1" position="float" orientation="portrait"><label>FigureÂ 1.</label><caption><p><bold>Flowchart of patient identification and distribution into respective cohorts.</bold> The entire cohort includes 132 patients with NGS of tumor samples. CCD wasÂ available for 87 patients, and 72 patients were managed by an MSK oncologist for their first-line treatment and had tumor NGS before or during CHOP-based treatment. CNS, central nervous system; CR1, first complete remission; EATL, enteropathy-associated T-cell lymphoma.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BLOODA_ADV-2023-009953-gr1.jpg"/></fig></p>
          <p id="p0080">Of the 87 patients in the CCD cohort, 26 (30%) were not included in the prospective cohort because they were not patients of MSK until after relapse or had MSK-IMPACT sequencing only after relapse. The prospective cohort consisted of 72 patients (55% of the entire cohort). There were 61 patients who were included in both the CCD cohort and the prospective cohort.</p>
        </sec>
        <sec id="sec3.2">
          <title>Baseline characteristics and treatments</title>
          <p id="p0085"><xref rid="tbl1" ref-type="table">TableÂ 1</xref> depicts the baseline characteristics of the entire cohort (NÂ = 132), CCD cohort (nÂ = 87), and prospective cohort (nÂ = 72) (note that throughout the manuscript and supplement, uppercase N denotes the entire cohort, whereas lowercase n denotes all other groups). Among the entire cohort, the median age at diagnosis was 65 years (range, 25-82 years) with a male predominance (61%; nÂ =Â 81). The most common histology was AITL, (47%; nÂ = 62) followed by PTCL-NOS (27%; nÂ = 36), ALK<sup>âˆ’</sup> ALCL (11%; nÂ = 15), PTCL-TFH (7%; nÂ = 9), ALK<sup>+</sup> ALCL (5%; nÂ = 6), and MEITL (3%; nÂ = 4). The majority of patients had advanced-stage disease (83%; nÂ = 110). Most patients in the CCD cohort had a low-intermediate to high-risk score on the international prognostic index (IPI; 81%; nÂ = 70) and a prognostic index for T-cell lymphomas (PIT) score of â‰¥2 (49%; nÂ = 43).<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref></p>
          <p id="p0090">The most common CHOP-based regimen was that containing etoposide, including both CHOP with etoposide (CHOEP) or etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) (45%; nÂ = 59) followed by CHOP (30%; nÂ = 40) or a CHOP-based clinical trial with the addition of a novel investigational drug (13%; nÂ = 17). BV-containing regimens were used in 16 patients (12%), including 9 of 21 patients with ALCL (43%). Of the total cohort, 50 patients (38%) received ASCT in first remission, and in the prospective cohort, 33 patients (46%) received ASCT in first remission, and 13 patients (10%) were treated on a maintenance therapy clinical trial protocol either after CHOP-based chemotherapy (nÂ = 3) or after ASCT consolidation (nÂ = 10).</p>
          <p id="p0095">There were no significant differences in any baseline clinical characteristic, chemotherapy regimen, or ASCT status among the 3 cohorts (<xref rid="tbl1" ref-type="table">TableÂ 1</xref>).</p>
        </sec>
        <sec id="sec3.3">
          <title>MSK-IMPACT results</title>
          <p id="p0100">Of the entire cohort, samples used for sequencing were most often taken from a lymph node biopsy (70%; nÂ = 93), whereas 8 (6%) had sequencing performed using a sample of leukemic blood or a biopsy of BM with disease involvement, and 31 (24%) came from other diseases sites. A patient-matched control was available in 103 (78%) cases, with those lacking a patient-matched control being matched to a pool of healthy donor control tissues (<xref rid="appsec1" ref-type="sec">supplemental TableÂ 1</xref>A).</p>
          <p id="p0105">Of the entire cohort, 87 patients (66%) had tumor samples sequenced upon initial diagnostic biopsy, 25 (19%) upon first relapse, and 20 (15%) beyond first relapse. For the CCD cohort, 64 patients (74%) had tumor samples sequenced upon initial diagnosis, 15 (17%) upon first relapse, and 8 (9%) beyond first relapse. By predetermined definition, all patients in the prospective cohort had sequencing performed using a diagnostic biopsy (<xref rid="appsec1" ref-type="sec">supplemental TableÂ 1</xref>A).</p>
          <p id="p0110">The most common mutations for the entire cohort were in <italic toggle="yes">TET2</italic> (52%; nÂ = 69), <italic toggle="yes">RHOA</italic> (30%; nÂ = 40), <italic toggle="yes">DNMT3A</italic> (19%; nÂ = 25), <italic toggle="yes">TP53</italic> (16%; nÂ = 21), and <italic toggle="yes">IDH2</italic> (11%; nÂ = 15). The most common CNAs were <italic toggle="yes">TP53</italic> deletions (7%; nÂ = 9) and <italic toggle="yes">CDKN2A</italic> deletions (7%; nÂ = 9) (<xref rid="fig2" ref-type="fig">FigureÂ 2</xref>; <xref rid="appsec1" ref-type="sec">supplemental TableÂ 1</xref>A-J).<fig id="fig2" position="float" orientation="portrait"><label>FigureÂ 2.</label><caption><p><bold>Oncoplot of the most frequent genetic aberrations in the entire cohort (NÂ = 132).</bold> Each column represents a unique patient. The top row represents both the number and type of alterations detected in each biopsy. Each row represents the diagnosis, biopsy, sequencing panel, gene and type of mutation, and/or CNA. Gray tiles indicate wild type. Missing tiles represent a gene that is not included in that specific NGS panel. Percent frequencies in the far-right column represent both mutations and CNAs for that specific gene.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BLOODA_ADV-2023-009953-gr2.jpg"/></fig></p>
          <p id="p0115">Among the 36 cases of PTCL-NOS, the most common mutations were in <italic toggle="yes">TP53</italic> (28%; nÂ = 10), and <italic toggle="yes">TET2</italic> (28%; nÂ = 10), followed by <italic toggle="yes">PLCG1</italic> (17%; nÂ = 6), <italic toggle="yes">STAT5B</italic> (11%; nÂ = 4), and <italic toggle="yes">KMT2D</italic> mutations (11%; nÂ = 4). <italic toggle="yes">TP53</italic> or 17p deletions (11%; nÂ = 4) were also observed. No patient had an <italic toggle="yes">IDH2</italic> mutation, and 2 patients (6%) had <italic toggle="yes">RHOA</italic> mutations (<xref rid="fig2" ref-type="fig">FigureÂ 2</xref>; <xref rid="appsec1" ref-type="sec">supplemental TableÂ 1</xref>B-C).</p>
          <p id="p0120">The most common aberrancy among the 62 cases of AITL were <italic toggle="yes">TET2</italic> mutations (82%; nÂ = 51) followed by mutations in <italic toggle="yes">RHOA</italic> (53%; nÂ =Â 33), <italic toggle="yes">DNMT3A</italic> (31%; nÂ = 19), and <italic toggle="yes">IDH2</italic> (23%; nÂ = 14). All <italic toggle="yes">IDH2</italic> mutations involved exon 4 at R172X. Of the 52 cases with <italic toggle="yes">TET2</italic> mutations, 36 (71%) had &gt;1 mutation in <italic toggle="yes">TET2</italic>. Of the 33 <italic toggle="yes">RHOA</italic> mutations, 29 (88%) were <italic toggle="yes">RHOA</italic> G17V mutations. <italic toggle="yes">TP53</italic> mutations (3%; nÂ = 2), <italic toggle="yes">TP53</italic> deletions (2%; nÂ = 1), and <italic toggle="yes">CDKN2A</italic> deletions (2%; nÂ = 1) were rare (<xref rid="fig2" ref-type="fig">FigureÂ 2</xref>; <xref rid="appsec1" ref-type="sec">supplemental TableÂ 1</xref>D-E).</p>
          <p id="p0125">The most common aberrancy among the 9 cases of PTCL-TFH were <italic toggle="yes">TET2</italic> mutations (67%; nÂ = 6) followed by mutations in <italic toggle="yes">RHOA</italic> (56%; nÂ = 5), <italic toggle="yes">DNMT3A</italic> (44%; nÂ = 4), <italic toggle="yes">TP53</italic> (22%; nÂ = 2), and <italic toggle="yes">TET3</italic> (22%; nÂ = 2) (<xref rid="fig2" ref-type="fig">FigureÂ 2</xref>; <xref rid="appsec1" ref-type="sec">supplemental TableÂ 1</xref>F-G).</p>
          <p id="p0130">The most common aberrancy among the 15 cases of ALK<sup>âˆ’</sup> ALCL were <italic toggle="yes">TP53</italic> mutations (33%; nÂ = 5), followed by <italic toggle="yes">TP53</italic> deletions (27%; nÂ = 4), <italic toggle="yes">STAT3</italic> mutations (20%; nÂ = 3), and <italic toggle="yes">FAT1</italic> mutations (20%; nÂ = 3) (<xref rid="fig2" ref-type="fig">FigureÂ 2</xref>; <xref rid="appsec1" ref-type="sec">supplemental TableÂ 1</xref>H-I). <italic toggle="yes">TP63</italic> and <italic toggle="yes">DUSP22/IRF4</italic> rearrangements were detected via other methodologies (fluorescence in-situ hybridization and/or RNA sequencing) in 3 (20%) and 2 (13%) cases, respectively, although not all cases of ALK<sup>âˆ’</sup> ALCL were evaluated for these structural variations via these other methodologies. No patient with either of these rearrangements had a <italic toggle="yes">TP53</italic> mutation.</p>
          <p id="p0135">Among this series of 132 cases, there were 6 cases of ALK<sup>+</sup> ALCL (5%) and 4 cases of MEITL (3%). Aside from ALK rearrangements, the most common aberrancies among the 6 cases of ALK<sup>+</sup> ALCL were <italic toggle="yes">FAT1</italic> mutations (33%; nÂ = 2), whereas <italic toggle="yes">TP53</italic> mutations occurred in 1 case (17%) (<xref rid="fig2" ref-type="fig">FigureÂ 2</xref>; <xref rid="appsec1" ref-type="sec">supplemental TableÂ 1</xref>H-I). Of the 4 cases of MEITL, 3 (75%) had <italic toggle="yes">CDKN2A</italic> aberrancies (mutation, nÂ = 1; deletions, nÂ = 2), 3 (75%) had <italic toggle="yes">SETD2</italic> mutations, and 1 (25%) had a <italic toggle="yes">TP53</italic> mutation (<xref rid="fig2" ref-type="fig">FigureÂ 2</xref>; <xref rid="appsec1" ref-type="sec">supplemental TableÂ 1</xref>J-K).</p>
        </sec>
        <sec id="sec3.4">
          <title>Responses and survival</title>
          <p id="p0140">The overall response rate was 69% (62% complete response [CR], nÂ = 82 and 7% partial response [PR], nÂ = 9) for the entire cohort, 73% (67% CR and 6% PR) for the CCD cohort, and 80% (74% CR and 6% PR) for the prospective cohort. The median follow-ups among survivors were 26, 23, and 24Â months for the entire cohort, CCD cohort, and prospective cohort, respectively (<xref rid="appsec1" ref-type="sec">supplemental TableÂ 2</xref>).</p>
          <p id="p0145">The median PFS was 9.4Â months (95% confidence interval [CI], 7.3-13.9) for the entire cohort, 10.8Â months (95%Â CI, 7.8-20.1) for the CCD cohort, and 19.1Â months (95%Â CI, 10.8-40.7) for the prospective cohort. The 2-year PFS was 28% (95%Â CI, 21.0-38.0) for the entire cohort, 34% (95%Â CI, 25.0-47.0) for the CCD cohort, and 43% (95%Â CI, 32.0-58.0) for the prospective cohort. Compared with the entire cohort, the prospective cohort had a longer PFS (<italic toggle="yes">P</italic>Â = .02), but otherwise, PFS did not differ based on the cohort (<xref rid="fig3" ref-type="fig">FigureÂ 3</xref>A; <xref rid="appsec1" ref-type="sec">supplemental TableÂ 2</xref>).<fig id="fig3" position="float" orientation="portrait"><label>FigureÂ 3.</label><caption><p><bold>Kaplan-Meier survival curves for each cohort.</bold> (A) PFS and (B) OS of the entire cohort (red), CCD cohort (blue), and prospective cohort (green). The prospective cohort had superior PFS compared with the entire cohort (<italic toggle="yes">P</italic>Â = .02). There were no other significant differences in PFS or OS. Living patients were censored at time of last follow-up (filled circles). The number of patients at risk for each time point and cohort is shown.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BLOODA_ADV-2023-009953-gr3.jpg"/></fig></p>
          <p id="p0150">The median OS was 53.2Â months (95%Â CI, 42.5-70.7) for the entire cohort, 56.7Â months (95%Â CI, 44.6 to not reached [NR]) for the CCD cohort, and NR (95%Â CI, 45.9-NR) for the prospective cohort. The 2-year OS was 74% (95%Â CI, 66.0-82.0) for the entire cohort, 73% (95%Â CI, 63.0-84.0) for the CCD cohort, and 77% (95%Â CI, 66.0-88.0) for the prospective cohort (<xref rid="fig3" ref-type="fig">FigureÂ 3</xref>B; <xref rid="appsec1" ref-type="sec">supplemental TableÂ 2</xref>). OS did not differ based on the cohort. PFS and OS did not differ based on the histology (<xref rid="appsec1" ref-type="sec">supplemental FigureÂ 1</xref>).</p>
        </sec>
        <sec id="sec3.5">
          <title>Clinical and genetic associations with survival</title>
          <p id="p0155">Factors affecting PFS in univariate analyses (<xref rid="tbl2" ref-type="table">TableÂ 2</xref>) were examined in a multivariate analysis. For the 87 patients in the CCD cohort, the clinical parameters correlating with inferior PFS on multivariate analysis were advanced-stage disease (HR, 5.1; 95%Â CI, 1.1-22.5; <italic toggle="yes">PÂ =</italic> .03) and BM involvement (HR, 3.0; 95%Â CI, 1.1-8.4; <italic toggle="yes">P</italic>Â = .04). Although higher IPI and PIT scores correlated with inferior PFS on univariate analysis, they lost significance upon multivariate analysis. No first-line treatment regimen correlated with PFS outcomes, but receipt of ASCT in first remission was associated with superior PFS (HR, 0.3; 95%Â CI, 0.1-0.5; <italic toggle="yes">P</italic>Â &lt; .001). The only 2 genetic aberrancies correlating with inferior PFS on multivariate analysis were <italic toggle="yes">TP53</italic> mutations (HR, 3.1; 95%Â CI, 1.4-6.8; <italic toggle="yes">P</italic>Â = .005) and <italic toggle="yes">TP53/</italic>17p deletions (HR, 4.1; 95%Â CI, 1.1-15.0; <italic toggle="yes">P</italic>Â = .03; <xref rid="tbl2" ref-type="table">TableÂ 2</xref>).<table-wrap position="float" id="tbl2" orientation="portrait"><label>TableÂ 2.</label><caption><p><bold>Variables correlating with inferior PFS in the CCD cohort (nÂ = 87)</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"><break/>Variable</th><th rowspan="2" colspan="1">n (%)</th><th colspan="3" rowspan="1">Univariate analysis<hr/></th><th colspan="3" rowspan="1">Multivariate analysis<hr/></th></tr><tr><th colspan="1" rowspan="1">HR</th><th colspan="1" rowspan="1">95%Â CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th><th colspan="1" rowspan="1">HR</th><th colspan="1" rowspan="1">95%Â CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Age &gt; 60 y</td><td align="char" colspan="1" rowspan="1">50 (57)</td><td align="char" colspan="1" rowspan="1">1.2</td><td align="char" colspan="1" rowspan="1">0.7-1.9</td><td align="char" colspan="1" rowspan="1">.56</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Stage III/IV</td><td align="char" colspan="1" rowspan="1">72 (83)</td><td align="char" colspan="1" rowspan="1">3.0</td><td align="char" colspan="1" rowspan="1">1.3-6.9</td><td align="char" colspan="1" rowspan="1"><bold>.01</bold></td><td align="char" colspan="1" rowspan="1">5.1</td><td align="char" colspan="1" rowspan="1">1.1-22.5</td><td align="char" colspan="1" rowspan="1"><bold>.03</bold></td></tr><tr><td colspan="1" rowspan="1">Performance: ECOG PS â‰¥ 2</td><td align="char" colspan="1" rowspan="1">10 (11)</td><td align="char" colspan="1" rowspan="1">1.9</td><td align="char" colspan="1" rowspan="1">0.9-3.7</td><td align="char" colspan="1" rowspan="1">.08</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">LDH elevated</td><td align="char" colspan="1" rowspan="1">53 (61)</td><td align="char" colspan="1" rowspan="1">1.1</td><td align="char" colspan="1" rowspan="1">0.7-1.9</td><td align="char" colspan="1" rowspan="1">.69</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">BM involvement (by morphological assessment)</td><td align="char" colspan="1" rowspan="1">32 (37)</td><td align="char" colspan="1" rowspan="1">2.3</td><td align="char" colspan="1" rowspan="1">1.4-3.9</td><td align="char" colspan="1" rowspan="1"><bold>.002</bold></td><td align="char" colspan="1" rowspan="1">3.0</td><td align="char" colspan="1" rowspan="1">1.1-8.4</td><td align="char" colspan="1" rowspan="1"><bold>.04</bold></td></tr><tr><td colspan="1" rowspan="1">Other extranodal sites of involvement</td><td align="char" colspan="1" rowspan="1">35 (40)</td><td align="char" colspan="1" rowspan="1">1.9</td><td align="char" colspan="1" rowspan="1">1.1-3.1</td><td align="char" colspan="1" rowspan="1"><bold>.01</bold></td><td align="char" colspan="1" rowspan="1">1.5</td><td align="char" colspan="1" rowspan="1">0.7-3.3</td><td align="char" colspan="1" rowspan="1">.32</td></tr><tr><td colspan="1" rowspan="1"><bold>IPI score</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â 0-1</td><td align="char" colspan="1" rowspan="1">17 (20)</td><td align="char" colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â 2</td><td align="char" colspan="1" rowspan="1">28 (32)</td><td align="char" colspan="1" rowspan="1">2.1</td><td align="char" colspan="1" rowspan="1">0.9-4.7</td><td align="char" colspan="1" rowspan="1">.08</td><td align="char" colspan="1" rowspan="1">1.0</td><td align="char" colspan="1" rowspan="1">0.2-4.3</td><td align="char" colspan="1" rowspan="1">.98</td></tr><tr><td colspan="1" rowspan="1">Â 3</td><td align="char" colspan="1" rowspan="1">30 (34)</td><td align="char" colspan="1" rowspan="1">2.9</td><td align="char" colspan="1" rowspan="1">1.3-6.5</td><td align="char" colspan="1" rowspan="1"><bold>.009</bold></td><td align="char" colspan="1" rowspan="1">0.4</td><td align="char" colspan="1" rowspan="1">0.1-2.8</td><td align="char" colspan="1" rowspan="1">.35</td></tr><tr><td colspan="1" rowspan="1">Â 4-5</td><td align="char" colspan="1" rowspan="1">12 (14)</td><td align="char" colspan="1" rowspan="1">2.8</td><td align="char" colspan="1" rowspan="1">1.1-7.0</td><td align="char" colspan="1" rowspan="1"><bold>.03</bold></td><td align="char" colspan="1" rowspan="1">0.1</td><td align="char" colspan="1" rowspan="1">0.01-2.0</td><td align="char" colspan="1" rowspan="1">.15</td></tr><tr><td colspan="1" rowspan="1"><bold>PIT score</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â 0-1</td><td align="char" colspan="1" rowspan="1">44 (51)</td><td align="char" colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â 2</td><td align="char" colspan="1" rowspan="1">24 (28)</td><td align="char" colspan="1" rowspan="1">1.3</td><td align="char" colspan="1" rowspan="1">0.7-2.4</td><td align="char" colspan="1" rowspan="1">.37</td><td align="char" colspan="1" rowspan="1">1.3</td><td align="char" colspan="1" rowspan="1">0.4-3.8</td><td align="char" colspan="1" rowspan="1">.65</td></tr><tr><td colspan="1" rowspan="1">Â 3-4</td><td align="char" colspan="1" rowspan="1">19 (22)</td><td align="char" colspan="1" rowspan="1">2.2</td><td align="char" colspan="1" rowspan="1">1.2-4.1</td><td align="char" colspan="1" rowspan="1"><bold>.01</bold></td><td align="char" colspan="1" rowspan="1">2.4</td><td align="char" colspan="1" rowspan="1">0.3-17.0</td><td align="char" colspan="1" rowspan="1">.41</td></tr><tr><td colspan="1" rowspan="1"><bold>Histology</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â PTCL-NOS</td><td align="char" colspan="1" rowspan="1">28 (32)</td><td align="char" colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â PTCL-TFH</td><td align="char" colspan="1" rowspan="1">6 (7)</td><td align="char" colspan="1" rowspan="1">0.3</td><td align="char" colspan="1" rowspan="1">0.1-1.1</td><td align="char" colspan="1" rowspan="1">.08</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â AITL</td><td align="char" colspan="1" rowspan="1">39 (45)</td><td align="char" colspan="1" rowspan="1">0.7</td><td align="char" colspan="1" rowspan="1">0.4-1.2</td><td align="char" colspan="1" rowspan="1">.14</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â ALK<sup>+</sup> ALCL</td><td align="char" colspan="1" rowspan="1">2 (2)</td><td align="char" colspan="1" rowspan="1">0.3</td><td align="char" colspan="1" rowspan="1">0.04-2.3</td><td align="char" colspan="1" rowspan="1">.24</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â ALK<sup>âˆ’</sup> ALCL</td><td align="char" colspan="1" rowspan="1">8 (9)</td><td align="char" colspan="1" rowspan="1">0.4</td><td align="char" colspan="1" rowspan="1">0.1-1.2</td><td align="char" colspan="1" rowspan="1">.10</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â MEITL</td><td align="char" colspan="1" rowspan="1">4 (5)</td><td align="char" colspan="1" rowspan="1">0.7</td><td align="char" colspan="1" rowspan="1">0.2-2.5</td><td align="char" colspan="1" rowspan="1">.61</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Use of etoposide-containing regimens</td><td align="char" colspan="1" rowspan="1">47 (54)</td><td align="char" colspan="1" rowspan="1">1.0</td><td align="char" colspan="1" rowspan="1">0.6-1.6</td><td align="char" colspan="1" rowspan="1">.91</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Use of BV-containing regimens</td><td align="char" colspan="1" rowspan="1">12 (14)</td><td align="char" colspan="1" rowspan="1">0.8</td><td align="char" colspan="1" rowspan="1">0.3-2.0</td><td align="char" colspan="1" rowspan="1">.65</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">ASCT consolidation</td><td align="char" colspan="1" rowspan="1">37 (43)</td><td align="char" colspan="1" rowspan="1">0.3</td><td align="char" colspan="1" rowspan="1">0.2-0.6</td><td align="char" colspan="1" rowspan="1"><bold>&lt;.001</bold></td><td align="char" colspan="1" rowspan="1">0.3</td><td align="char" colspan="1" rowspan="1">0.1-0.5</td><td align="char" colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">Maintenance<xref rid="tbl2fnlowast" ref-type="table-fn">âˆ—</xref></td><td align="char" colspan="1" rowspan="1">12 (14)</td><td align="char" colspan="1" rowspan="1">0.4</td><td align="char" colspan="1" rowspan="1">0.2-1.0</td><td align="char" colspan="1" rowspan="1"><bold>.04</bold></td><td align="char" colspan="1" rowspan="1">0.4</td><td align="char" colspan="1" rowspan="1">0.1-1.0</td><td align="char" colspan="1" rowspan="1">.051</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">TP53</italic> mutation</td><td align="char" colspan="1" rowspan="1">13 (15)</td><td align="char" colspan="1" rowspan="1">2.4</td><td align="char" colspan="1" rowspan="1">1.3-4.6</td><td align="char" colspan="1" rowspan="1"><bold>.008</bold></td><td align="char" colspan="1" rowspan="1">3.1</td><td align="char" colspan="1" rowspan="1">1.4-6.8</td><td align="char" colspan="1" rowspan="1"><bold>.005</bold></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">TP53</italic> or 17p deletion</td><td align="char" colspan="1" rowspan="1">5 (6)</td><td align="char" colspan="1" rowspan="1">9.6</td><td align="char" colspan="1" rowspan="1">3.4-27.2</td><td align="char" colspan="1" rowspan="1"><bold>&lt;.001</bold></td><td align="char" colspan="1" rowspan="1">4.1</td><td align="char" colspan="1" rowspan="1">1.1-15.0</td><td align="char" colspan="1" rowspan="1"><bold>.03</bold></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">CDKN2A</italic> deletion</td><td align="char" colspan="1" rowspan="1">7 (8)</td><td align="char" colspan="1" rowspan="1">2.2</td><td align="char" colspan="1" rowspan="1">0.9-5.1</td><td align="char" colspan="1" rowspan="1">.07</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">TET2</italic> mutation</td><td align="char" colspan="1" rowspan="1">48 (55)</td><td align="char" colspan="1" rowspan="1">0.9</td><td align="char" colspan="1" rowspan="1">0.5-1.5</td><td align="char" colspan="1" rowspan="1">.69</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">DNMT3A</italic> mutation</td><td align="char" colspan="1" rowspan="1">17 (20)</td><td align="char" colspan="1" rowspan="1">1.4</td><td align="char" colspan="1" rowspan="1">0.8-2.5</td><td align="char" colspan="1" rowspan="1">.27</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">DNMT3A</italic> exon 23 mutation</td><td align="char" colspan="1" rowspan="1">5 (6)</td><td align="char" colspan="1" rowspan="1">1.4</td><td align="char" colspan="1" rowspan="1">0.6-3.6</td><td align="char" colspan="1" rowspan="1">.44</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">RHOA</italic> mutation</td><td align="char" colspan="1" rowspan="1">26 (30)</td><td align="char" colspan="1" rowspan="1">0.8</td><td align="char" colspan="1" rowspan="1">0.4-1.3</td><td align="char" colspan="1" rowspan="1">.34</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">FAT1</italic> mutation</td><td align="char" colspan="1" rowspan="1">4 (5)</td><td align="char" colspan="1" rowspan="1">1.1</td><td align="char" colspan="1" rowspan="1">0.3-3.4</td><td align="char" colspan="1" rowspan="1">.92</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">STAT3</italic> mutation</td><td align="char" colspan="1" rowspan="1">4 (5)</td><td align="char" colspan="1" rowspan="1">1.0</td><td align="char" colspan="1" rowspan="1">0.3-3.3</td><td align="char" colspan="1" rowspan="1">.94</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">SETD2</italic> mutation</td><td align="char" colspan="1" rowspan="1">5 (6)</td><td align="char" colspan="1" rowspan="1">0.5</td><td align="char" colspan="1" rowspan="1">0.2-1.6</td><td align="char" colspan="1" rowspan="1">.24</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">IDH2</italic> mutation</td><td align="char" colspan="1" rowspan="1">7 (8)</td><td align="char" colspan="1" rowspan="1">0.6</td><td align="char" colspan="1" rowspan="1">0.2-1.7</td><td align="char" colspan="1" rowspan="1">.33</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">PCLG1</italic> mutation</td><td align="char" colspan="1" rowspan="1">7 (8)</td><td align="char" colspan="1" rowspan="1">1.2</td><td align="char" colspan="1" rowspan="1">0.5-2.9</td><td align="char" colspan="1" rowspan="1">.76</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Total number of aberrancies</td><td align="char" colspan="1" rowspan="1">87 (100)</td><td align="char" colspan="1" rowspan="1">1.0</td><td align="char" colspan="1" rowspan="1">1.0-1.1</td><td align="char" colspan="1" rowspan="1">.07</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tspara0025"><p>ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase.</p></fn><fn id="tspara0015z"><p>Bold indicates <italic toggle="yes">P</italic> &lt; .05.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnlowast"><label>âˆ—</label><p id="ntpara0030">Twelve patients received maintenance systemic therapy on a clinical trial either after chemotherapy or after ASCT.</p></fn></table-wrap-foot></table-wrap></p>
          <p id="p0160">Factors affecting the OS in univariate analyses (<xref rid="tbl3" ref-type="table">TableÂ 3</xref>) were examined in a multivariate analysis. The only baseline clinical parameter correlating with inferior OS on multivariate analysis was an Eastern Cooperative Oncology Group performance status score of â‰¥2 (HR, 19.2; 95%Â CI, 2.8-133.0; <italic toggle="yes">P</italic>Â = .003). ASCT receipt during the first remission remained significant for a superior OS upon multivariate analysis (HR, 0.1; 95%Â CI, 0.04-0.4; <italic toggle="yes">P</italic>Â &lt;Â .001). The only genetic aberrancy correlating with inferior OS was the presence of a <italic toggle="yes">CDKN2A</italic> deletion (HR, 12.1; 95%Â CI, 2.8-52.0; <italic toggle="yes">P</italic>Â &lt; .001). In contrast to PFS, <italic toggle="yes">TP53</italic> alterations did not correlate with inferior OS (<xref rid="tbl3" ref-type="table">TableÂ 3</xref>).<table-wrap position="float" id="tbl3" orientation="portrait"><label>TableÂ 3.</label><caption><p><bold>Variables correlating with inferior OS in the CCD cohort (nÂ = 87)</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"><break/>Variable</th><th rowspan="2" colspan="1">n (%)</th><th colspan="3" rowspan="1">Univariate analysis<hr/></th><th colspan="3" rowspan="1">Multivariate analysis<hr/></th></tr><tr><th colspan="1" rowspan="1">HR</th><th colspan="1" rowspan="1">95%Â CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th><th colspan="1" rowspan="1">HR</th><th colspan="1" rowspan="1">95%Â CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Age &gt; 60 y</td><td align="char" colspan="1" rowspan="1">50 (57)</td><td align="char" colspan="1" rowspan="1">1.3</td><td align="char" colspan="1" rowspan="1">0.6-2.7</td><td align="char" colspan="1" rowspan="1">.54</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Stage III/IV</td><td align="char" colspan="1" rowspan="1">72 (83)</td><td align="char" colspan="1" rowspan="1">2.7</td><td align="char" colspan="1" rowspan="1">0.6-11.4</td><td align="char" colspan="1" rowspan="1">.18</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Performance: ECOG PS â‰¥ 2</td><td align="char" colspan="1" rowspan="1">10 (11)</td><td align="char" colspan="1" rowspan="1">3.6</td><td align="char" colspan="1" rowspan="1">1.6-8.0</td><td align="char" colspan="1" rowspan="1"><bold>.002</bold></td><td align="char" colspan="1" rowspan="1">19.2</td><td align="char" colspan="1" rowspan="1">2.8-133.0</td><td align="char" colspan="1" rowspan="1"><bold>.003</bold></td></tr><tr><td colspan="1" rowspan="1">LDH elevated</td><td align="char" colspan="1" rowspan="1">53 (61)</td><td align="char" colspan="1" rowspan="1">2.4</td><td align="char" colspan="1" rowspan="1">1.1-5.7</td><td align="char" colspan="1" rowspan="1"><bold>.04</bold></td><td align="char" colspan="1" rowspan="1">1.9</td><td align="char" colspan="1" rowspan="1">0.5-7.2</td><td align="char" colspan="1" rowspan="1">.33</td></tr><tr><td colspan="1" rowspan="1">BM involvement (by morphological assessment)</td><td align="char" colspan="1" rowspan="1">32 (37)</td><td align="char" colspan="1" rowspan="1">3.4</td><td align="char" colspan="1" rowspan="1">1.7-7.0</td><td align="char" colspan="1" rowspan="1"><bold>&lt;.001</bold></td><td align="char" colspan="1" rowspan="1">3.8</td><td align="char" colspan="1" rowspan="1">0.8-19.0</td><td align="char" colspan="1" rowspan="1">.10</td></tr><tr><td colspan="1" rowspan="1">Other extranodal sites of involvement</td><td align="char" colspan="1" rowspan="1">35 (40)</td><td align="char" colspan="1" rowspan="1">2.1</td><td align="char" colspan="1" rowspan="1">1.0-4.2</td><td align="char" colspan="1" rowspan="1"><bold>.04</bold></td><td align="char" colspan="1" rowspan="1">1.0</td><td align="char" colspan="1" rowspan="1">0.2-4.5</td><td align="char" colspan="1" rowspan="1">.96</td></tr><tr><td colspan="1" rowspan="1"><bold>IPI score, n (%)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â 0-1 (group 1)</td><td align="char" colspan="1" rowspan="1">17 (20)</td><td align="char" colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â 2 (group 2)</td><td align="char" colspan="1" rowspan="1">28 (32)</td><td align="char" colspan="1" rowspan="1">4.4</td><td align="char" colspan="1" rowspan="1">0.5-35.0</td><td align="char" colspan="1" rowspan="1">.16</td><td align="char" colspan="1" rowspan="1">7.8</td><td align="char" colspan="1" rowspan="1">0.8-73.0</td><td align="char" colspan="1" rowspan="1">.07</td></tr><tr><td colspan="1" rowspan="1">Â 3 (group 3)</td><td align="char" colspan="1" rowspan="1">30 (34)</td><td align="char" colspan="1" rowspan="1">7.5</td><td align="char" colspan="1" rowspan="1">1.0-57.0</td><td align="char" colspan="1" rowspan="1"><bold>.052</bold></td><td align="char" colspan="1" rowspan="1">2.1</td><td align="char" colspan="1" rowspan="1">0.1-28.0</td><td align="char" colspan="1" rowspan="1">.59</td></tr><tr><td colspan="1" rowspan="1">Â 4-5 (group 4)</td><td align="char" colspan="1" rowspan="1">12 (14)</td><td align="char" colspan="1" rowspan="1">11.8</td><td align="char" colspan="1" rowspan="1">1.5-95.0</td><td align="char" colspan="1" rowspan="1"><bold>.02</bold></td><td align="char" colspan="1" rowspan="1">0.4</td><td align="char" colspan="1" rowspan="1">0.01-21.0</td><td align="char" colspan="1" rowspan="1">.64</td></tr><tr><td colspan="1" rowspan="1"><bold>PIT score, n (%)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â 0-1 (group 1)</td><td align="char" colspan="1" rowspan="1">44 (51)</td><td align="char" colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â 2 (group 2)</td><td align="char" colspan="1" rowspan="1">24 (28)</td><td align="char" colspan="1" rowspan="1">2.1</td><td align="char" colspan="1" rowspan="1">0.8-5.2.0</td><td align="char" colspan="1" rowspan="1">.13</td><td align="char" colspan="1" rowspan="1">0.8</td><td align="char" colspan="1" rowspan="1">0.2-3.5</td><td align="char" colspan="1" rowspan="1">.76</td></tr><tr><td colspan="1" rowspan="1">Â 3-4 (group 3)</td><td align="char" colspan="1" rowspan="1">19 (22)</td><td align="char" colspan="1" rowspan="1">4.3</td><td align="char" colspan="1" rowspan="1">1.8-10.0</td><td align="char" colspan="1" rowspan="1"><bold>&lt;.001</bold></td><td align="char" colspan="1" rowspan="1">1.3</td><td align="char" colspan="1" rowspan="1">0.1-30.0</td><td align="char" colspan="1" rowspan="1">.87</td></tr><tr><td colspan="1" rowspan="1"><bold>Histology</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â PTCL-NOS</td><td align="char" colspan="1" rowspan="1">28 (32)</td><td align="char" colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â PTCL-TFH</td><td align="char" colspan="1" rowspan="1">6 (7)</td><td align="char" colspan="1" rowspan="1">1.0</td><td align="char" colspan="1" rowspan="1">0.2-4.3</td><td align="char" colspan="1" rowspan="1">.95</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â AITL</td><td align="char" colspan="1" rowspan="1">39 (45)</td><td align="char" colspan="1" rowspan="1">0.8</td><td align="char" colspan="1" rowspan="1">0.4-1.8</td><td align="char" colspan="1" rowspan="1">.61</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â ALK<sup>+</sup> ALCL</td><td align="char" colspan="1" rowspan="1">2 (2)</td><td align="char" colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">-</td><td align="char" colspan="1" rowspan="1">.99</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â ALK<sup>âˆ’</sup> ALCL</td><td align="char" colspan="1" rowspan="1">8 (9)</td><td align="char" colspan="1" rowspan="1">0.3</td><td align="char" colspan="1" rowspan="1">0.04-2.4</td><td align="char" colspan="1" rowspan="1">.26</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â MEITL</td><td align="char" colspan="1" rowspan="1">4 (5)</td><td align="char" colspan="1" rowspan="1">0.9</td><td align="char" colspan="1" rowspan="1">0.1-7.1</td><td align="char" colspan="1" rowspan="1">.93</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Use of etoposide-containing regimens</td><td align="char" colspan="1" rowspan="1">47 (54)</td><td align="char" colspan="1" rowspan="1">0.7</td><td align="char" colspan="1" rowspan="1">0.3-1.3</td><td align="char" colspan="1" rowspan="1">.25</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Use of BV-containing regimens</td><td align="char" colspan="1" rowspan="1">12 (14)</td><td align="char" colspan="1" rowspan="1">1.9</td><td align="char" colspan="1" rowspan="1">0.6-6.5</td><td align="char" colspan="1" rowspan="1">.31</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">ASCT consolidation</td><td align="char" colspan="1" rowspan="1">37 (43)</td><td align="char" colspan="1" rowspan="1">0.2</td><td align="char" colspan="1" rowspan="1">0.1-0.5</td><td align="char" colspan="1" rowspan="1"><bold>&lt;.001</bold></td><td align="char" colspan="1" rowspan="1">0.1</td><td align="char" colspan="1" rowspan="1">0.04-0.40</td><td align="char" colspan="1" rowspan="1"><bold>&lt; .001</bold></td></tr><tr><td colspan="1" rowspan="1">Maintenance therapy<xref rid="tbl3fnlowast" ref-type="table-fn">âˆ—</xref></td><td align="char" colspan="1" rowspan="1">12 (14)</td><td align="char" colspan="1" rowspan="1">0.4</td><td align="char" colspan="1" rowspan="1">0.1-1.2</td><td align="char" colspan="1" rowspan="1">.09</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">TP53</italic> mutation</td><td align="char" colspan="1" rowspan="1">13 (15)</td><td align="char" colspan="1" rowspan="1">0.7</td><td align="char" colspan="1" rowspan="1">0.2-1.9</td><td align="char" colspan="1" rowspan="1">.45</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">TP53</italic> or 17p deletion</td><td align="char" colspan="1" rowspan="1">5 (6)</td><td align="char" colspan="1" rowspan="1">1.4</td><td align="char" colspan="1" rowspan="1">0.3-6.0</td><td align="char" colspan="1" rowspan="1">.63</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">CDKN2A</italic> deletion</td><td align="char" colspan="1" rowspan="1">7 (8)</td><td align="char" colspan="1" rowspan="1">5.3</td><td align="char" colspan="1" rowspan="1">1.9-14.4</td><td align="char" colspan="1" rowspan="1"><bold>.001</bold></td><td align="char" colspan="1" rowspan="1">12.1</td><td align="char" colspan="1" rowspan="1">2.8-52.0</td><td align="char" colspan="1" rowspan="1"><bold>&lt; .001</bold></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">TET2</italic> mutation</td><td align="char" colspan="1" rowspan="1">48 (55)</td><td align="char" colspan="1" rowspan="1">1.3</td><td align="char" colspan="1" rowspan="1">0.6-2.7</td><td align="char" colspan="1" rowspan="1">.47</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">DNMT3A</italic> mutation</td><td align="char" colspan="1" rowspan="1">17 (20)</td><td align="char" colspan="1" rowspan="1">1.6</td><td align="char" colspan="1" rowspan="1">0.7-3.6</td><td align="char" colspan="1" rowspan="1">.25</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">DNMT3A</italic> exon 23 mutation</td><td align="char" colspan="1" rowspan="1">5 (6)</td><td align="char" colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">-</td><td align="char" colspan="1" rowspan="1">.99</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">RHOA</italic> mutation</td><td align="char" colspan="1" rowspan="1">26 (30)</td><td align="char" colspan="1" rowspan="1">0.9</td><td align="char" colspan="1" rowspan="1">0.4-2.0</td><td align="char" colspan="1" rowspan="1">.79</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">FAT1</italic> mutation</td><td align="char" colspan="1" rowspan="1">4 (5)</td><td align="char" colspan="1" rowspan="1">1.9</td><td align="char" colspan="1" rowspan="1">0.4-8.1</td><td align="char" colspan="1" rowspan="1">.40</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">STAT3</italic> mutation</td><td align="char" colspan="1" rowspan="1">4 (5)</td><td align="char" colspan="1" rowspan="1">1.1</td><td align="char" colspan="1" rowspan="1">0.2-8.5</td><td align="char" colspan="1" rowspan="1">.90</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">SETD2</italic> mutation</td><td align="char" colspan="1" rowspan="1">5 (6)</td><td align="char" colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">-</td><td align="char" colspan="1" rowspan="1">.99</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">IDH2</italic> mutation</td><td align="char" colspan="1" rowspan="1">7 (8)</td><td align="char" colspan="1" rowspan="1">2.0</td><td align="char" colspan="1" rowspan="1">0.7-5.8</td><td align="char" colspan="1" rowspan="1">.19</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">PCLG1</italic> mutation</td><td align="char" colspan="1" rowspan="1">7 (8)</td><td align="char" colspan="1" rowspan="1">2.1</td><td align="char" colspan="1" rowspan="1">0.6-7.2</td><td align="char" colspan="1" rowspan="1">.22</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Total number of aberrancies</td><td align="char" colspan="1" rowspan="1">87 (100)</td><td align="char" colspan="1" rowspan="1">1.0</td><td align="char" colspan="1" rowspan="1">1.0-1.1</td><td align="char" colspan="1" rowspan="1"><bold>.04</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tspara0035"><p>ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase.</p></fn><fn id="tspara0010z"><p>Bold indicates <italic toggle="yes">P</italic> &lt; .05.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnlowast"><label>âˆ—</label><p id="ntpara0035">Twelve patients received maintenance systemic therapy on a clinical trial either after chemotherapy or after ASCT.</p></fn></table-wrap-foot></table-wrap></p>
        </sec>
        <sec id="sec3.6">
          <title>Cohort-wide survival based on <italic toggle="yes">TP53</italic> and <italic toggle="yes">CDKN2A</italic> status</title>
          <p id="p0165">Cases harboring either a <italic toggle="yes">TP53</italic> mutation or a <italic toggle="yes">TP53</italic>/17p deletion in the CCD cohort correlated with inferior PFS on multivariate analysis. Therefore, we stratified the entire cohort based on the presence (16%; nÂ = 21) or absence (84%; nÂ = 111) of a <italic toggle="yes">TP53</italic> mutation (with or without a <italic toggle="yes">TP53</italic>/17p deletion). Of the 21 cases with <italic toggle="yes">TP53</italic> mutations, 15 (71%) did not have a concurrent <italic toggle="yes">TP53</italic>/17p deletion, and 6 (29%) had a concurrent <italic toggle="yes">TP53</italic>/17p deletion. Two cases (10%) had a concurrent <italic toggle="yes">CDKN2A</italic> deletion, 1 of which also had a concurrent <italic toggle="yes">TP53</italic>/17p deletion. A <italic toggle="yes">TP53/</italic>17p deletion without a concurrent <italic toggle="yes">TP53</italic> mutation was found in only 3 cases (2%) of the entire cohort.</p>
          <p id="p0170">Among the entire cohort of PTCL, patients with <italic toggle="yes">TP53</italic> mutations had inferior PFS, with a median PFS of 4.5Â months (95%Â CI, 3.8-13.9) vs 10.5Â months (95%Â CI, 7.8-18.1) for those without <italic toggle="yes">TP53</italic> mutations (<italic toggle="yes">P</italic>Â &lt; .001) (<xref rid="fig4" ref-type="fig">FigureÂ 4</xref>A; <xref rid="appsec1" ref-type="sec">supplemental TableÂ 3</xref>). The 2-year PFS was 10% (95%Â CI, 3.0-36.0) in <italic toggle="yes">TP53-</italic>mutated PTCL and 32% (95%Â CI, 24.0-43.0) in <italic toggle="yes">TP53-</italic>unmutated PTCL (<xref rid="appsec1" ref-type="sec">supplemental TableÂ 3</xref>). All PFS events for patients with <italic toggle="yes">TP53</italic>-mutated PTCL were due to relapsed or refractory disease. In the prospective cohort, the median PFS was 4.1Â months (95%Â CI, 2.8-NR) for patients with <italic toggle="yes">TP53-</italic>mutated PTCL vs 19.7Â months (95%Â CI, 10.8-72.3) for those with <italic toggle="yes">TP53</italic>-unmutated PTCL (<italic toggle="yes">P</italic>Â = .02; <xref rid="appsec1" ref-type="sec">supplemental FigureÂ 2</xref>A; <xref rid="appsec1" ref-type="sec">supplemental TableÂ 4</xref>).<fig id="fig4" position="float" orientation="portrait"><label>FigureÂ 4.</label><caption><p><bold>Kaplan-Meier survival curves for the entire cohort (NÂ = 132) stratified based on the <italic toggle="yes">TP53</italic> mutation status.</bold> (A) PFS and (B) OS of patients with (<italic toggle="yes">TP53-</italic>mutated; red) or without (<italic toggle="yes">TP53-</italic>unmutated; blue) PTCL. Data of living patients were censored at the time of last follow-up (filled circles). The number of patients at risk for each time point and cohort is shown.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BLOODA_ADV-2023-009953-gr4.jpg"/></fig></p>
          <p id="p0175">There were no significant differences in the OS of patients with <italic toggle="yes">TP53</italic>-mutated PTCL compared with that of those with <italic toggle="yes">TP53</italic>-unmutated PTCL in either the entire or prospective cohorts. For the entire cohort, the median OS of patients with <italic toggle="yes">TP53</italic>-mutated PTCL was 48.2Â months (95%Â CI, 29.2-NR) vs 53.2Â months (95%Â CI, 42.3-71) for those with <italic toggle="yes">TP53</italic>-umutated PTCL (<xref rid="fig4" ref-type="fig">FigureÂ 4</xref>B; <xref rid="appsec1" ref-type="sec">supplemental TableÂ 3</xref>). In the prospective cohort, the median OS was NR (95%Â CI, NA-NA) for patients with <italic toggle="yes">TP53</italic>-mutated PTCL vs 58.7Â months (95%Â CI, 45.9-NR) for those with <italic toggle="yes">TP53</italic>-unmutated PTCL (<xref rid="appsec1" ref-type="sec">supplemental FigureÂ 2</xref>B; <xref rid="appsec1" ref-type="sec">supplemental TableÂ 4</xref>).</p>
          <p id="p0180"><italic toggle="yes">CDKN2A</italic> deletions correlated with inferior OS upon multivariate analysis in the CCD cohort. Therefore, we compared the OS of the entire cohort with that of the prospective cohort based on the presence (7%; nÂ = 9) or absence (93%; nÂ = 123) of <italic toggle="yes">CDKN2A</italic> deletions. Of the 9 cases with a <italic toggle="yes">CDKN2A</italic> deletion, 2 (22%) had a concurrent <italic toggle="yes">TP53</italic>/17p deletion, and 2 (22%) had a concurrent <italic toggle="yes">TP53</italic> mutation. For the entire cohort, <italic toggle="yes">CDKN2A</italic>-deleted PTCL correlated with an inferior OS, with a median of 17.6Â months (95%Â CI, 12.8-NR) vs 56.7Â months (95%Â CI, 44.6-101.0) for PTCL without <italic toggle="yes">CDKN2A</italic> deletions (<italic toggle="yes">P</italic>Â = .004; <xref rid="appsec1" ref-type="sec">supplemental FigureÂ 3</xref>B; <xref rid="appsec1" ref-type="sec">supplemental TableÂ 3</xref>). PFS trended but remained nonsignificant based on the presence or absence of <italic toggle="yes">CDKN2A</italic> deletions (<xref rid="appsec1" ref-type="sec">supplemental FigureÂ 3</xref>A; <xref rid="appsec1" ref-type="sec">supplemental TableÂ 3</xref>). There were only 4 cases (5%) with <italic toggle="yes">CDKN2A</italic> deletions in the prospective cohort (<xref rid="appsec1" ref-type="sec">supplemental TableÂ 4</xref>).</p>
          <p id="p0185">Consistent with prior reports, <italic toggle="yes">TP53</italic> mutations (3%; nÂ = 2) and <italic toggle="yes">CDKN2A</italic> deletions (nÂ = 0) were rare in AITL.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> Therefore, we analyzed the survival rates of non-AITL PTCL (nÂ = 70) based on the presence or absence of these alterations. Patients with <italic toggle="yes">TP53</italic>-mutated non-AITL PTCL experienced inferior PFS, with a median of 4.5Â months (95%Â CI, 4.1-17.4) vs 7.8Â months (95%Â CI, 7.1-20.1) for <italic toggle="yes">TP53</italic>-unmutated non-AITL PTCL (<italic toggle="yes">P</italic>Â = .02), with no difference in the OS (<xref rid="appsec1" ref-type="sec">supplemental FigureÂ 4</xref>; <xref rid="appsec1" ref-type="sec">supplemental TableÂ 5</xref>). Patients with non-AITL PTCL harboring <italic toggle="yes">CDKN2A</italic> deletions had inferior OS, with a median OS of 17.4Â months (95%Â CI, 11.1-NR) forÂ patients with <italic toggle="yes">CDKN2A</italic> deletions vs 48.2Â months (95%Â CI, 42.5-NR) for those without such deletions (<italic toggle="yes">P</italic>Â = .004). There was no difference in the PFS based on the <italic toggle="yes">CDKN2A</italic> status (<xref rid="appsec1" ref-type="sec">supplemental FigureÂ 5</xref>; <xref rid="appsec1" ref-type="sec">supplemental TableÂ 5</xref>).</p>
          <p id="p0190"><italic toggle="yes">TP53</italic>/17p deletions were uncommon in the absence of a <italic toggle="yes">TP53</italic> mutation (2%; nÂ = 3). There were no differences in PFS when both <italic toggle="yes">TP53</italic>/17p deletion and <italic toggle="yes">TP53</italic> mutation were present as compared with a <italic toggle="yes">TP53</italic> mutation alone (<xref rid="appsec1" ref-type="sec">supplemental FigureÂ 6</xref>).</p>
        </sec>
        <sec id="sec3.7">
          <title>Characteristics of <italic toggle="yes">TP53</italic>-mutated PTCL</title>
          <p id="p0195">We then compared the characteristics and treatment outcomes for patients with <italic toggle="yes">TP53</italic>-mutated PTCL vs <italic toggle="yes">TP53</italic>-unmutated PTCL (<xref rid="tbl4" ref-type="table">TableÂ 4</xref>). <italic toggle="yes">TP53</italic> mutations were relatively enriched in PTCL-NOS (nÂ = 10; <italic toggle="yes">PÂ =</italic> .03) and relatively less frequent in AITL (nÂ = 2; <italic toggle="yes">P</italic>Â &lt; .001) compared with other histologies. There were no significant differences in age, disease stage, BM involvement, involvement of other extranodal sites, or IPI or PIT scores between patients with <italic toggle="yes">TP53</italic>-mutated and <italic toggle="yes">TP53</italic>-unmutated PTCL. There were also no differences in first-line treatment regimen or whether ASCT was received in first remission. There was a trend toward fewer CRs for patients with <italic toggle="yes">TP53</italic>-mutated PTCL (<italic toggle="yes">P</italic>Â = .053).<table-wrap position="float" id="tbl4" orientation="portrait"><label>TableÂ 4.</label><caption><p><bold>Characteristics and outcomes for patients with <italic toggle="yes">TP53</italic>-mutated vs <italic toggle="yes">TP53</italic>-unmutated PTCL</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"><italic toggle="yes">TP53</italic> mutated (nÂ = 21)</th><th colspan="1" rowspan="1"><italic toggle="yes">TP53</italic> unmutated (nÂ = 111)</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Median age, y (range)</td><td align="char" colspan="1" rowspan="1">60 (46-79)</td><td align="char" colspan="1" rowspan="1">66 (25-82)</td><td align="char" colspan="1" rowspan="1">.39</td></tr><tr><td colspan="1" rowspan="1"><bold>Sex, n (%)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â Male</td><td align="char" colspan="1" rowspan="1">16 (76)</td><td align="char" colspan="1" rowspan="1">65 (59)</td><td align="char" colspan="1" rowspan="1">.15</td></tr><tr><td colspan="1" rowspan="1">Â Female</td><td align="char" colspan="1" rowspan="1">5 (24)</td><td align="char" colspan="1" rowspan="1">46 (41)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Histology, n (% frequency per histology)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â PTCL-NOS</td><td align="char" colspan="1" rowspan="1">10/36 (28)</td><td align="char" colspan="1" rowspan="1">26/36 (72)</td><td align="char" colspan="1" rowspan="1"><bold>.03</bold></td></tr><tr><td colspan="1" rowspan="1">Â AITL</td><td align="char" colspan="1" rowspan="1">2/62 (3)</td><td align="char" colspan="1" rowspan="1">60/62 (97)</td><td align="char" colspan="1" rowspan="1"><bold>&lt; .001</bold></td></tr><tr><td colspan="1" rowspan="1">Â PTCL-TFH</td><td align="char" colspan="1" rowspan="1">2/9 (22)</td><td align="char" colspan="1" rowspan="1">7/9 (78)</td><td align="char" colspan="1" rowspan="1">.63</td></tr><tr><td colspan="1" rowspan="1">Â ALK<sup>âˆ’</sup> ALCL</td><td align="char" colspan="1" rowspan="1">5/15 (33)</td><td align="char" colspan="1" rowspan="1">10/15 (67)</td><td align="char" colspan="1" rowspan="1">.06</td></tr><tr><td colspan="1" rowspan="1">Â ALK<sup>+</sup> ALCL</td><td align="char" colspan="1" rowspan="1">1/6 (17)</td><td align="char" colspan="1" rowspan="1">5/6 (83)</td><td align="char" colspan="1" rowspan="1">&gt;.99</td></tr><tr><td colspan="1" rowspan="1">Â MEITL</td><td align="char" colspan="1" rowspan="1">1/4 (25)</td><td align="char" colspan="1" rowspan="1">3/4 (75)</td><td align="char" colspan="1" rowspan="1">.50</td></tr><tr><td colspan="1" rowspan="1"><bold>Stage, n (%)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â I/II<xref rid="tbl4fnlowast" ref-type="table-fn">âˆ—</xref></td><td align="char" colspan="1" rowspan="1">5 (24)</td><td align="char" colspan="1" rowspan="1">17 (15)</td><td align="char" colspan="1" rowspan="1">.35</td></tr><tr><td colspan="1" rowspan="1">Â III/IV<xref rid="tbl4fnlowast" ref-type="table-fn">âˆ—</xref></td><td align="char" colspan="1" rowspan="1">16 (76)</td><td align="char" colspan="1" rowspan="1">94 (85)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>BM involvement by (by morphological assessment), n (%)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â N</td><td align="char" colspan="1" rowspan="1">13 (62)</td><td align="char" colspan="1" rowspan="1">59 (53)</td><td align="char" colspan="1" rowspan="1">.17</td></tr><tr><td colspan="1" rowspan="1">Â Y</td><td align="char" colspan="1" rowspan="1">3 (14)</td><td align="char" colspan="1" rowspan="1">36 (32)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â Unconfirmed</td><td align="char" colspan="1" rowspan="1">5 (24)</td><td align="char" colspan="1" rowspan="1">16 (14)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Other extranodal sites of involvement, n (%)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â N</td><td align="char" colspan="1" rowspan="1">12 (57)</td><td align="char" colspan="1" rowspan="1">69 (62)</td><td align="char" colspan="1" rowspan="1">.81</td></tr><tr><td colspan="1" rowspan="1">Â Y</td><td align="char" colspan="1" rowspan="1">9 (43)</td><td align="char" colspan="1" rowspan="1">42 (38)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>IPI score, n (%)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â 0-1</td><td align="char" colspan="1" rowspan="1">2 (10)</td><td align="char" colspan="1" rowspan="1">17 (15)</td><td align="char" colspan="1" rowspan="1">.80</td></tr><tr><td colspan="1" rowspan="1">Â 2</td><td align="char" colspan="1" rowspan="1">5 (24)</td><td align="char" colspan="1" rowspan="1">26 (23)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â 3</td><td align="char" colspan="1" rowspan="1">5 (24)</td><td align="char" colspan="1" rowspan="1">25 (23)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â 4-5</td><td align="char" colspan="1" rowspan="1">1 (5)</td><td align="char" colspan="1" rowspan="1">15 (14)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â Incomplete data</td><td align="char" colspan="1" rowspan="1">8 (38)</td><td align="char" colspan="1" rowspan="1">28 (25)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>PIT score, n (%)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â 0-1</td><td align="char" colspan="1" rowspan="1">8 (38)</td><td align="char" colspan="1" rowspan="1">36 (32)</td><td align="char" colspan="1" rowspan="1">.79</td></tr><tr><td colspan="1" rowspan="1">Â 2</td><td align="char" colspan="1" rowspan="1">3 (14)</td><td align="char" colspan="1" rowspan="1">21 (19)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â 3-4</td><td align="char" colspan="1" rowspan="1">2 (10)</td><td align="char" colspan="1" rowspan="1">17 (15)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â Incomplete data</td><td align="char" colspan="1" rowspan="1">8 (38)</td><td align="char" colspan="1" rowspan="1">37 (33)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>First-line treatment, n (%)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â CHOP</td><td align="char" colspan="1" rowspan="1">4 (19)</td><td align="char" colspan="1" rowspan="1">36 (32)</td><td align="char" colspan="1" rowspan="1">.16</td></tr><tr><td colspan="1" rowspan="1">Â CHOEP/EPOCH</td><td align="char" colspan="1" rowspan="1">11 (52)</td><td align="char" colspan="1" rowspan="1">48 (43)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â BV-CH(E)P</td><td align="char" colspan="1" rowspan="1">5 (24)</td><td align="char" colspan="1" rowspan="1">11 (10)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â CHOP-basedÂ + novel agent</td><td align="char" colspan="1" rowspan="1">1 (5)</td><td align="char" colspan="1" rowspan="1">16 (14)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Response to induction, n (%)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â CR</td><td align="char" colspan="1" rowspan="1">9 (43)</td><td align="char" colspan="1" rowspan="1">73 (66)</td><td align="char" colspan="1" rowspan="1">.053</td></tr><tr><td colspan="1" rowspan="1">Â &lt;CR</td><td align="char" colspan="1" rowspan="1">12 (57)</td><td align="char" colspan="1" rowspan="1">38 (34)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Received ASCT in first remission, n (%)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â Y</td><td align="char" colspan="1" rowspan="1">6 (29)</td><td align="char" colspan="1" rowspan="1">44 (40)</td><td align="char" colspan="1" rowspan="1">.17</td></tr><tr><td colspan="1" rowspan="1">Â N</td><td align="char" colspan="1" rowspan="1">15 (71)</td><td align="char" colspan="1" rowspan="1">67 (60)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Outcomes after ASCT, n (%)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â PFS event</td><td align="char" colspan="1" rowspan="1">5/6 (83)</td><td align="char" colspan="1" rowspan="1">29/44 (66)</td><td align="char" colspan="1" rowspan="1">.65</td></tr><tr><td colspan="1" rowspan="1">Â Ongoing remission</td><td align="char" colspan="1" rowspan="1">1/6 (17)</td><td align="char" colspan="1" rowspan="1">15/44 (34)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>MSK-IMPACT sample sequencing time point, n (%)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â Diagnostic biopsy</td><td align="char" colspan="1" rowspan="1">10 (48)</td><td align="char" colspan="1" rowspan="1">77 (69)</td><td align="char" colspan="1" rowspan="1">.09</td></tr><tr><td colspan="1" rowspan="1">Â First relapse biopsy</td><td align="char" colspan="1" rowspan="1">5 (24)</td><td align="char" colspan="1" rowspan="1">20 (18)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â Beyond first relapse</td><td align="char" colspan="1" rowspan="1">6 (29)</td><td align="char" colspan="1" rowspan="1">14 (13)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Other aberrancies, n (%)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Â <italic toggle="yes">TP53</italic> or 17p deletion</td><td align="char" colspan="1" rowspan="1">6 (29)</td><td align="char" colspan="1" rowspan="1">3 (3)</td><td align="char" colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">Â <italic toggle="yes">CDKN2A</italic> deletion or mutation</td><td align="char" colspan="1" rowspan="1">3 (14)</td><td align="char" colspan="1" rowspan="1">9 (8)</td><td align="char" colspan="1" rowspan="1">.41</td></tr><tr><td colspan="1" rowspan="1">Â <italic toggle="yes">DNMT3A</italic> mutation</td><td align="char" colspan="1" rowspan="1">2 (10)</td><td align="char" colspan="1" rowspan="1">23 (21)</td><td align="char" colspan="1" rowspan="1">.36</td></tr><tr><td colspan="1" rowspan="1">Â <italic toggle="yes">TET2</italic> mutation</td><td align="char" colspan="1" rowspan="1">6 (29)</td><td align="char" colspan="1" rowspan="1">63 (57)</td><td align="char" colspan="1" rowspan="1"><bold>.03</bold></td></tr><tr><td colspan="1" rowspan="1">Â <italic toggle="yes">RHOA</italic></td><td align="char" colspan="1" rowspan="1">2 (10)</td><td align="char" colspan="1" rowspan="1">38 (34)</td><td align="char" colspan="1" rowspan="1"><bold>.04</bold></td></tr><tr><td colspan="1" rowspan="1">Â <italic toggle="yes">IDH2</italic></td><td align="char" colspan="1" rowspan="1">0 (0)</td><td align="char" colspan="1" rowspan="1">15 (13)</td><td align="char" colspan="1" rowspan="1">.13</td></tr><tr><td colspan="1" rowspan="1">Â Median number of aberrancies (range)</td><td align="char" colspan="1" rowspan="1">11 (1-48)</td><td align="char" colspan="1" rowspan="1">5 (0-33)</td><td align="char" colspan="1" rowspan="1"><bold>.008</bold></td></tr></tbody></table><table-wrap-foot><fn id="tspara0045"><p>BV-CH(E)P, CHOP with brentuximab vedotin in place of vincristine with or without etoposide; CHOEP, CHOP with etoposide; N, no; Y, yes.</p></fn><fn id="tspara0005a"><p>Bold indicates <italic toggle="yes">P</italic> &lt; .05.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl4fnlowast"><label>âˆ—</label><p id="ntpara0040">One patient with documented stage II disease and 8 patients with documented stage III disease based on imaging were missing baseline BM biopsies.</p></fn></table-wrap-foot></table-wrap></p>
          <p id="p0200">Similar proportions of patients with <italic toggle="yes">TP53</italic>-mutated and <italic toggle="yes">TP53</italic>-unmutated PTCL had sequencing performed using their initial diagnostic biopsy. <italic toggle="yes">TP53</italic> mutations were more likely to cooccur with <italic toggle="yes">TP53</italic> or 17p deletions (<italic toggle="yes">P &lt;</italic> .001), whereas <italic toggle="yes">TET2</italic> and <italic toggle="yes">RHOA</italic> mutations were enriched in patients with PTCL without <italic toggle="yes">TP53-</italic>mutations (<italic toggle="yes">P</italic>Â = .03 and <italic toggle="yes">P</italic>Â = .04, respectively). <italic toggle="yes">TET2</italic> and <italic toggle="yes">TP53</italic> mutations cooccurred in 6 cases. None of the 15 patients with an <italic toggle="yes">IDH2</italic> mutation had a concurrent <italic toggle="yes">TP53</italic> mutation. Cases with mutated <italic toggle="yes">TP53</italic> had a higher median number of total aberrancies per sample (<italic toggle="yes">PÂ =</italic> .008; <xref rid="tbl4" ref-type="table">TableÂ 4</xref>).</p>
          <p id="p0205">Lastly, for all cases of PTCL with a <italic toggle="yes">TP53</italic> mutation (16%; nÂ = 21), we compared the median variant allele frequency of the <italic toggle="yes">TP53</italic> mutation to all other concurrent mutations within each patientâ€™s biopsy (<xref rid="fig5" ref-type="fig">FigureÂ 5</xref>A). <italic toggle="yes">TP53</italic> mutations were the dominant mutation in 12 cases (57%), at or above the median of all mutations in 18 cases (86%). The majority of <italic toggle="yes">TP53</italic> mutations involved the DNA binding domain (81%; nÂ = 17) and were missense mutations (52%; nÂ = 11; <xref rid="fig5" ref-type="fig">FigureÂ 5</xref>B). All the <italic toggle="yes">TP53</italic> mutations had been reported previously as a cancer hotspot mutation and/or are documented in the OncoKB database as being likely oncogenic.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><fig id="fig5" position="float" orientation="portrait"><label>FigureÂ 5.</label><caption><p><bold><italic toggle="yes">TP53</italic> median variant allele frequencies (MAFs) and mutation specifics among PTCL cases with a <italic toggle="yes">TP53</italic> mutation (nÂ = 21).</bold> (A) MAF of <italic toggle="yes">TP53</italic> mutations asÂ compared with all other gene mutations in each tumor sample (nÂ = 21). Each of these 21 patientsâ€™ biopsies are represented on the x-axis. Red symbols represent the MAF of the <italic toggle="yes">TP53</italic> mutation. Black symbols represent the MAF of any non-<italic toggle="yes">TP53â€“</italic>mutated gene found in the same biopsy. The solid lines represent the median MAF of all mutations occurring in the biopsy sample. (B) Lollipop plot of <italic toggle="yes">TP53</italic> mutations (nÂ = 21). Each colored symbol represents a specific <italic toggle="yes">TP53</italic> mutation along the entire coding region. The green boxed region represents the transactivation domain (P53_TAD). The red boxed region represents the DNA binding domain (P53). The blue boxed region represents the tetramerization domain (P53_tetramer). The next 2 rows signify that all mutations are listed in the OncoKB database as likely oncogenic, and 15 have been reported as cancer hotspot mutations. The bottom row illustrates the exon structure of the <italic toggle="yes">TP53</italic> gene.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="BLOODA_ADV-2023-009953-gr5.jpg"/></fig></p>
        </sec>
      </sec>
      <sec id="sec4">
        <title>Discussion</title>
        <p id="p0210">To the best of our knowledge, these data represent the largest cohort of patients with PTCL treated with curative-intent chemotherapy to undergo targeted NGS of their tumors using a clinically validated sequencing panel. We centered on histologies treated with CHOP-based regimens with the option of ASCT consolidation, when eligible. Upon multivariate analysis in the CCD cohort, <italic toggle="yes">TP53</italic> alterations were detected as the only genetic event that independently predicted inferior PFS; this result was observed in both the entire and prospective cohorts when stratified based on the presence or absence of a <italic toggle="yes">TP53</italic> mutation. In addition, <italic toggle="yes">TP53</italic>-mutated PTCL showed a trend toward a lower frequency of CRs compared with <italic toggle="yes">TP53</italic>-unmutated PTCL, suggesting inherent chemoresistance in these cases. This is consistent with the observations of patients with <italic toggle="yes">TP53</italic> alterations in other hematological malignancies in which <italic toggle="yes">TP53</italic> alterations associate with inferior outcomes when treated with both curative- and noncurative-intent therapies.<xref rid="bib32" ref-type="bibr">32</xref>, <xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref></p>
        <p id="p0215">The <italic toggle="yes">TP53</italic> mutations in our cohort were highly suggestive of a predominant clone based on the high allele frequency observed in all but 1 case. The relatively high prevalence of <italic toggle="yes">TP53</italic> mutations in PTCL-NOS (28%) and ALK<sup>âˆ’</sup> ALCL (33%) in this series was similar to prior reports. For example, 2 independent publications on PTCL-NOS reported the presence of <italic toggle="yes">TP53</italic> mutations in 28% and 19% of cases, respectively.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> In a recent large series of patients with systemic ALCL (NÂ = 82), <italic toggle="yes">TP53</italic> mutations occurred in 23% of ALK<sup>âˆ’</sup> and 11% of ALK<sup>+</sup> ALCL cases, respectively, and correlated with inferior PFS and OS.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref>
<italic toggle="yes">TP53</italic> mutations in our series were rare in AITL (3%), consistent with prior reports.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> Based on previous observations, <italic toggle="yes">TP53</italic> mutations occured in âˆ¼17% to 40% of PTCL-TFH cases<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> and 33% of MEITL cases.<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> Overall, our data on the prevalence of <italic toggle="yes">TP53</italic> mutations in PTCL are consistent with prior observations.</p>
        <p id="p0220">Interestingly, although patients with <italic toggle="yes">TP53</italic> mutations experienced inferior PFS, they had no impact on OS. We hypothesized that this could have been attributed to the inclusion of multiple histologies, access to multiple novel clinical trials implementing non-cytotoxic therapies, and/or variability in eligibility for curative-intent allogeneic stem cell transplant. However, only 3 (10%) patients with <italic toggle="yes">TP5</italic>3-mutated PTCL underwent curative-intent allo-SCT after CHOP-based progression, and all 3 relapsed. One of these patients achieved a second CR with duvelisib plus romidepsin, was consolidated with donor lymphocyte infusion, and has remains disease-free for &gt;5 years.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> Nevertheless, despite the low number of patients with <italic toggle="yes">TP53</italic>-mutated PTCL who underwent a potentially curative allo-SCT, the median number of lines of therapy was 3 (range, 1-11), and 10 (48%) patients received â‰¥4 lines of therapy (data not shown). Moreover, 10 (48%) patients were treated on a least 1 clinical trial investigating novel therapies such as valemetostat, duvelisib, duvelisib plus romidepsin, ruxolitinib, or cerdulatinib; all of which have demonstrated relatively encouraging response rates and durability in a subset of patients.<xref rid="bib40" ref-type="bibr">40</xref>, <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref> This suggests novel agents may provide meaningful outcomes for <italic toggle="yes">TP53</italic>-mutated PTCL. A dedicated analysis on the outcomes of relapsed or refractory <italic toggle="yes">TP53</italic>-mutated PTCL compared with non-<italic toggle="yes">TP53</italic>-mutated PTCL is needed to better understand this patient population and determine the best treatment strategies.</p>
        <p id="p0225">Multivariate analyses in the CCD cohort and the entire cohort indicated that patients with <italic toggle="yes">CDKN2A</italic> deletions experienced inferior OS when compared to patients who did not harbor such deletions. Using various methodologies for CNA detection combined with other published datasets, a recent study reported a high frequency (46%) of these deletions in PTCL-NOS and their significant association with inferior PFS and OS.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref>
<italic toggle="yes">CDKN2A</italic> deletions were rare in our cohort (7% of entire cohort and 8% in PTCL-NOS), possibly restricted by the threshold of CNA detection through exome sequencing and the clinical reporting of MSK-IMPACT limiting definitive conclusions based on our data alone.</p>
        <p id="p0230">Limitations to this retrospective study include the small numbers of patients with certain histologic subsets, patients for whom data on baseline clinical characteristics were missing, lack of uniform treatment for patients, lack of complete PTCL-TFH immunohistochemical markers in older cases, and the limitations of MSK-IMPACT methodologies in detecting CNAs and other structural variations. There are also limitations with targeted exon sequencing and the threshold for calling chromosome arm-level deletions and copy-neutral loss of heterozygosity with MSK-IMPACT. Given these limitations, caution is advised when interpreting these data for first-line treatment modifications and should not reflexively institute deviations in the current standard of care including enrollment onto first-line clinical trials.</p>
        <p id="p0235">Despite some limitations, we found that 95% of patients (20 of 21) with <italic toggle="yes">TP53-</italic>mutated PTCL in our study had relapsed after, or were refractory to, curative-intent treatment with CHOP-based therapy. Other than <italic toggle="yes">TP53</italic> mutations, as described in this manuscript and in others, additional genetic markers including GATA-3 expression, <italic toggle="yes">FAT1</italic> mutations, and <italic toggle="yes">CDKN2A</italic> deletions in PTCL-NOS, <italic toggle="yes">CD28</italic> mutations in AITL, and <italic toggle="yes">TP63</italic> structural variations in ALK<sup>âˆ’</sup> ALCL have been previously reported as indicators of a poor prognosis.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> Whether <italic toggle="yes">TP53</italic> aberrancies or other genetic events require an alternative approach to therapeutic induction and/or consolidative strategies will require further research on a larger cohort of patients who are uniformly treated.</p>
      </sec>
      <sec sec-type="COI-statement">
        <p id="p0240">Conflict-of-interest disclosure: W.T.J. received consulting fees from Myeloid Therapeutics. A.J.M. received research support from <funding-source id="gs3">ADC Therapeutics</funding-source>, <funding-source id="gs4"><institution-wrap><institution-id institution-id-type="doi">10.13039/100017239</institution-id><institution>BeiGene</institution></institution-wrap></funding-source>, <funding-source id="gs5">Miragen</funding-source>, <funding-source id="gs6"><institution-wrap><institution-id institution-id-type="doi">10.13039/100010293</institution-id><institution>Seattle Genetics</institution></institution-wrap></funding-source>, <funding-source id="gs7"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004334</institution-id><institution>Merck</institution></institution-wrap></funding-source>, <funding-source id="gs8"><institution-wrap><institution-id institution-id-type="doi">10.13039/100002491</institution-id><institution>Bristol Myers Squibb</institution></institution-wrap></funding-source>, <funding-source id="gs9"><institution-wrap><institution-id institution-id-type="doi">10.13039/100017655</institution-id><institution>Incyte</institution></institution-wrap></funding-source>, and <funding-source id="gs10">SecuraBio, and</funding-source> received honoraria from Affimed, Imbrium Therapeutics LP/Purdue, Janpix Ltd, Merck, Seattle Genetics, and Takeda. N.K. received research support from <funding-source id="gs11"><institution-wrap><institution-id institution-id-type="doi">10.13039/100010293</institution-id><institution>Seattle Genetics</institution></institution-wrap></funding-source>. A.D.Z. received consulting fees from Genentech/Roche, Gilead, Celgene, Janssen, Amgen, Novartis, Adaptive Biotechnology, MorphoSys, AbbVie, AstraZeneca, and MEI Pharma; received research funding from <funding-source id="gs12">MEI Pharmaceuticals</funding-source>, <funding-source id="gs13"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004328</institution-id><institution>Genentech</institution></institution-wrap></funding-source>/<funding-source id="gs14"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004337</institution-id><institution>Roche</institution></institution-wrap></funding-source>, <funding-source id="gs15"><institution-wrap><institution-id institution-id-type="doi">10.13039/100017239</institution-id><institution>BeiGene</institution></institution-wrap></funding-source>, and <funding-source id="gs16"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000002</institution-id><institution>NIH</institution></institution-wrap></funding-source>/NCI SPORE in Lymphoma (P50 CA192937-06A1); and served in data monitoring committees for BeiGene (Chair) and Bristol Myers Squibb/Celgene/Juno. M.L.P. received advisory/consulting fees from Novartis, Synthekine, BeiGene, Kite, and MustangBio. M.J.M. received honoraria from Genentech, Roche, GlaxoSmithKline, Bayer, Pharmacyclics, Janssen, Seattle Genetics, Immunovaccine Technologies, Takeda, and Epizyme; received advisory/consulting fees from Genentech, Bayer, Merck, Juno Therapeutics, Roche, Teva, Rocket Medical, Seattle Genetics, Daiichi Sankyo, Takeda, and Epizyme; and received research funding from <funding-source id="gs17"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004328</institution-id><institution>Genentech, Roche</institution></institution-wrap></funding-source>, <funding-source id="gs19">GlaxoSmithKline</funding-source>, <funding-source id="gs20">IGM Biosciences</funding-source>, <funding-source id="gs21"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004326</institution-id><institution>Bayer</institution></institution-wrap></funding-source>, <funding-source id="gs22"><institution-wrap><institution-id institution-id-type="doi">10.13039/100014491</institution-id><institution>Pharmacyclics</institution></institution-wrap></funding-source>, <funding-source id="gs23"><institution-wrap><institution-id institution-id-type="doi">10.13039/100005565</institution-id><institution>Janssen</institution></institution-wrap></funding-source>, <funding-source id="gs24">Rocket Medical</funding-source>, <funding-source id="gs25"><institution-wrap><institution-id institution-id-type="doi">10.13039/100010293</institution-id><institution>Seattle Genetics</institution></institution-wrap></funding-source>, and <funding-source id="gs26">Immunovaccine Technologies</funding-source>. A.N. received research funding from <funding-source id="gs27"><institution-wrap><institution-id institution-id-type="doi">10.13039/100014491</institution-id><institution>Pharmacyclics</institution></institution-wrap></funding-source>/AbbVie, <funding-source id="gs29">Kite</funding-source>/<funding-source id="gs30"><institution-wrap><institution-id institution-id-type="doi">10.13039/100005564</institution-id><institution>Gilead</institution></institution-wrap></funding-source>, and <funding-source id="gs31">Cornerstone</funding-source>; received consulting fees from Janssen, Morphosys, Cornerstone, Epizyme, EUSA, TG therapeutics, ADC Therapeutics, and AstraZeneca; and received honoraria from Pharmacyclics/AbbVie. P.C.C. holds stock/stock options in Bristol Myers Squibb, Johnson &amp; Johnson, Pfizer, AstraZeneca, GlaxoSmithKline, and Novartis. C.L.B. is employed by Genentech. A.K. received research funding from <funding-source id="gs32">AbbVie Pharmaceuticals</funding-source>, <funding-source id="gs33"><institution-wrap><institution-id institution-id-type="doi">10.13039/100016796</institution-id><institution>Adaptive Biotechnologies</institution></institution-wrap></funding-source>, <funding-source id="gs34"><institution-wrap><institution-id institution-id-type="doi">10.13039/100006436</institution-id><institution>Celgene</institution></institution-wrap></funding-source>, <funding-source id="gs35"><institution-wrap><institution-id institution-id-type="doi">10.13039/100014491</institution-id><institution>Pharmacyclics</institution></institution-wrap></funding-source>, <funding-source id="gs36"><institution-wrap><institution-id institution-id-type="doi">10.13039/100010293</institution-id><institution>Seattle Genetics</institution></institution-wrap></funding-source>, <funding-source id="gs37"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004325</institution-id><institution>AstraZeneca</institution></institution-wrap></funding-source>, and <funding-source id="gs38"><institution-wrap><institution-id institution-id-type="doi">10.13039/100016936</institution-id><institution>Loxo Oncology</institution></institution-wrap></funding-source>/<funding-source id="gs39"><institution-wrap><institution-id institution-id-type="doi">10.13039/100022186</institution-id><institution>Lilly</institution></institution-wrap></funding-source>, and served in an advisory role for Celgene, Genentech, Kite Pharmaceuticals, Loxo Oncology/Lilly, and AstraZeneca. C.S.S. provided consulting for Juno Therapeutics, Sanofi-Genzyme, Spectrum Pharmaceuticals, Novartis, Genmab, Precision Biosciences, Kite/Gilead, Celgene/Bristol Myers Squibb, Gamida Cell, Karyopharm Therapeutics, Ono Pharmaceuticals, MorphoSys, CSL Behring, Syncopation Life Sciences, CRISPR Therapeutics, and GlaxoSmithKline, and received research funding from Juno Therapeutics, Celgene/Bristol Myers Squibb, Precision Biosciences, Actinium Pharmaceuticals, and Sanofi-Genzyme. L.F. received research funding and consulting fees from Genmab, AbbVie, and Roche/Genentech; received honoraria from and served on advisory boards for ADC Therapeutics, Seattle Genetics, and AstraZeneca. J.K.L. received consulting fees from TG Therapeutics and Epizyme. S.A.V. served on advisory board for Immunai, and received consulting fees from ADC Therapeutics and Koch Disruptive Technologies. G.S. served on advisory boards for and received consulting fees from AbbVie, Bayer, BeiGene, Bristol Myers Squibb/Celgene, Epizyme, Genentech/Roche, Genmab, Incyte, Ipsen, Janssen, Kite/Gilead, Loxo, Miltenyi, Molecular Partners, MorphoSys, Nordic Nanovector, Novartis, Rapt, Regeneron, and Takeda, and owns shares in Owkin. A.D. provided consulting for Incyte, EUSA Pharma, and Loxo, and received research support from <funding-source id="gs40"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004337</institution-id><institution>Roche</institution></institution-wrap></funding-source> and <funding-source id="gs41"><institution-wrap><institution-id institution-id-type="doi">10.13039/100007723</institution-id><institution>Takeda</institution></institution-wrap></funding-source>. S.M.H. received research funding from <funding-source id="gs42">ADC Therapeutics</funding-source>, <funding-source id="gs43">Affimed</funding-source>, <funding-source id="gs44"><institution-wrap><institution-id institution-id-type="doi">10.13039/100018559</institution-id><institution>Aileron</institution></institution-wrap></funding-source>, <funding-source id="gs45"><institution-wrap><institution-id institution-id-type="doi">10.13039/100006436</institution-id><institution>Celgene</institution></institution-wrap></funding-source>, <funding-source id="gs46">CRISPR Therapeutics</funding-source>, <funding-source id="gs47"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100022274</institution-id><institution>Daiichi Sankyo</institution></institution-wrap></funding-source>, <funding-source id="gs48">Forty Seven Inc</funding-source>, <funding-source id="gs49"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004095</institution-id><institution>Kyowa Hakko Kirin</institution></institution-wrap></funding-source>, <funding-source id="gs50">Millennium</funding-source>/<funding-source id="gs51"><institution-wrap><institution-id institution-id-type="doi">10.13039/100007723</institution-id><institution>Takeda</institution></institution-wrap></funding-source>, <funding-source id="gs52"><institution-wrap><institution-id institution-id-type="doi">10.13039/100010293</institution-id><institution>Seattle Genetics</institution></institution-wrap></funding-source>, <funding-source id="gs53">Trillium Therapeutics</funding-source>, and <funding-source id="gs54">Verastem</funding-source>/<funding-source id="gs55">Secura Bio</funding-source>, and received consulting fees from Acrotech Biopharma, ADC Therapeutics, Astex, Auxilus Pharma, Merck, C4 Therapeutics, Celgene, Cimieo Therapeutics, Daiichi Sankyo, Janssen, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, ONO Pharmaceuticals, Seattle Genetics, Secura Bio, Shoreline Biosciences Inc, Takeda, Trillium Therapeutics, Tubulis, Verastem/Secura Bio, Vividion Therapeutics, and Yingli Pharma Ltd. The remaining authors declare no competing financial interests.</p>
        <p id="p0245">A.M.H. is a retired member of the faculty of Memorial Sloan Kettering Cancer Center, New York, NY.</p>
        <p id="p0250">The current affiliation for C.L.B. is Genentech, South San Francisco, CA.</p>
      </sec>
    </body>
    <back>
      <ref-list id="cebib0010">
        <title>References</title>
        <ref id="bib1">
          <label>1</label>
          <element-citation publication-type="journal" id="sref1">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Swerdlow</surname>
                <given-names>SH</given-names>
              </name>
              <name name-style="western">
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
              <name name-style="western">
                <surname>Pileri</surname>
                <given-names>SA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The 2016 revision of the World Health Organization classification of lymphoid neoplasms</article-title>
            <source>Blood</source>
            <volume>127</volume>
            <issue>20</issue>
            <year>2016</year>
            <fpage>2375</fpage>
            <lpage>2390</lpage>
            <pub-id pub-id-type="pmid">26980727</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2016-01-643569</pub-id>
            <pub-id pub-id-type="pmcid">PMC4874220</pub-id>
          </element-citation>
        </ref>
        <ref id="bib2">
          <label>2</label>
          <element-citation publication-type="journal" id="sref2">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Vose</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Armitage</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Weisenburger</surname>
                <given-names>D</given-names>
              </name>
              <collab>International T-Cell Lymphoma Project</collab>
            </person-group>
            <article-title>International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes</article-title>
            <source>JÂ Clin Oncol</source>
            <volume>26</volume>
            <issue>25</issue>
            <year>2008</year>
            <fpage>4124</fpage>
            <lpage>4130</lpage>
            <pub-id pub-id-type="pmid">18626005</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2008.16.4558</pub-id>
          </element-citation>
        </ref>
        <ref id="bib3">
          <label>3</label>
          <element-citation publication-type="journal" id="sref3">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Carson</surname>
                <given-names>KR</given-names>
              </name>
              <name name-style="western">
                <surname>Horwitz</surname>
                <given-names>SM</given-names>
              </name>
              <name name-style="western">
                <surname>Pinter-Brown</surname>
                <given-names>LC</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>AÂ prospective cohort study of patients with peripheral T-cell lymphoma in the United States</article-title>
            <source>Cancer</source>
            <volume>123</volume>
            <issue>7</issue>
            <year>2017</year>
            <fpage>1174</fpage>
            <lpage>1183</lpage>
            <pub-id pub-id-type="pmid">27911989</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.30416</pub-id>
            <pub-id pub-id-type="pmcid">PMC5650190</pub-id>
          </element-citation>
        </ref>
        <ref id="bib4">
          <label>4</label>
          <element-citation publication-type="journal" id="sref4">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ellin</surname>
                <given-names>F</given-names>
              </name>
              <name name-style="western">
                <surname>Landstrom</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Jerkeman</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Relander</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry</article-title>
            <source>Blood</source>
            <volume>124</volume>
            <issue>10</issue>
            <year>2014</year>
            <fpage>1570</fpage>
            <lpage>1577</lpage>
            <pub-id pub-id-type="pmid">25006130</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2014-04-573089</pub-id>
          </element-citation>
        </ref>
        <ref id="bib5">
          <label>5</label>
          <element-citation publication-type="journal" id="sref5">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Iqbal</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Wright</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma</article-title>
            <source>Blood</source>
            <volume>123</volume>
            <issue>19</issue>
            <year>2014</year>
            <fpage>2915</fpage>
            <lpage>2923</lpage>
            <pub-id pub-id-type="pmid">24632715</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2013-11-536359</pub-id>
            <pub-id pub-id-type="pmcid">PMC4014836</pub-id>
          </element-citation>
        </ref>
        <ref id="bib6">
          <label>6</label>
          <element-citation publication-type="journal" id="sref6">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Maura</surname>
                <given-names>F</given-names>
              </name>
              <name name-style="western">
                <surname>Agnelli</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Leongamornlert</surname>
                <given-names>D</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma</article-title>
            <source>Am J Hematol</source>
            <volume>94</volume>
            <issue>6</issue>
            <year>2019</year>
            <fpage>628</fpage>
            <lpage>634</lpage>
            <pub-id pub-id-type="pmid">30829413</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ajh.25450</pub-id>
            <pub-id pub-id-type="pmcid">PMC6684242</pub-id>
          </element-citation>
        </ref>
        <ref id="bib7">
          <label>7</label>
          <element-citation publication-type="journal" id="sref7">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Parrilla Castellar</surname>
                <given-names>ER</given-names>
              </name>
              <name name-style="western">
                <surname>Jaffe</surname>
                <given-names>ES</given-names>
              </name>
              <name name-style="western">
                <surname>Said</surname>
                <given-names>JW</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes</article-title>
            <source>Blood</source>
            <volume>124</volume>
            <issue>9</issue>
            <year>2014</year>
            <fpage>1473</fpage>
            <lpage>1480</lpage>
            <pub-id pub-id-type="pmid">24894770</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2014-04-571091</pub-id>
            <pub-id pub-id-type="pmcid">PMC4148769</pub-id>
          </element-citation>
        </ref>
        <ref id="bib8">
          <label>8</label>
          <element-citation publication-type="journal" id="sref8">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Piccaluga</surname>
                <given-names>PP</given-names>
              </name>
              <name name-style="western">
                <surname>Fuligni</surname>
                <given-names>F</given-names>
              </name>
              <name name-style="western">
                <surname>De Leo</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study</article-title>
            <source>JÂ Clin Oncol</source>
            <volume>31</volume>
            <issue>24</issue>
            <year>2013</year>
            <fpage>3019</fpage>
            <lpage>3025</lpage>
            <pub-id pub-id-type="pmid">23857971</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2012.42.5611</pub-id>
          </element-citation>
        </ref>
        <ref id="bib9">
          <label>9</label>
          <element-citation publication-type="journal" id="sref9">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Horwitz</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>O'Connor</surname>
                <given-names>OA</given-names>
              </name>
              <name name-style="western">
                <surname>Pro</surname>
                <given-names>B</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial</article-title>
            <source>Lancet</source>
            <volume>393</volume>
            <issue>10168</issue>
            <year>2019</year>
            <fpage>229</fpage>
            <lpage>240</lpage>
            <pub-id pub-id-type="pmid">30522922</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(18)32984-2</pub-id>
            <pub-id pub-id-type="pmcid">PMC6436818</pub-id>
          </element-citation>
        </ref>
        <ref id="bib10">
          <label>10</label>
          <element-citation publication-type="journal" id="sref10">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Schmitz</surname>
                <given-names>N</given-names>
              </name>
              <name name-style="western">
                <surname>Trumper</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Ziepert</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group</article-title>
            <source>Blood</source>
            <volume>116</volume>
            <issue>18</issue>
            <year>2010</year>
            <fpage>3418</fpage>
            <lpage>3425</lpage>
            <pub-id pub-id-type="pmid">20660290</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2010-02-270785</pub-id>
          </element-citation>
        </ref>
        <ref id="bib11">
          <label>11</label>
          <element-citation publication-type="journal" id="sref11">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Brink</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Meeuwes</surname>
                <given-names>FO</given-names>
              </name>
              <name name-style="western">
                <surname>van der Poel</surname>
                <given-names>MWM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Impact of etoposide and ASCT on survival among patients aged &lt;65 years with stage II to IV PTCL: a population-based cohort study</article-title>
            <source>Blood</source>
            <volume>140</volume>
            <issue>9</issue>
            <year>2022</year>
            <fpage>1009</fpage>
            <lpage>1019</lpage>
            <pub-id pub-id-type="pmid">35544601</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood.2021015114</pub-id>
            <pub-id pub-id-type="pmcid">PMC9437712</pub-id>
          </element-citation>
        </ref>
        <ref id="bib12">
          <label>12</label>
          <element-citation publication-type="journal" id="sref12">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>d'Amore</surname>
                <given-names>F</given-names>
              </name>
              <name name-style="western">
                <surname>Relander</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Lauritzsen</surname>
                <given-names>GF</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01</article-title>
            <source>JÂ Clin Oncol</source>
            <volume>30</volume>
            <issue>25</issue>
            <year>2012</year>
            <fpage>3093</fpage>
            <lpage>3099</lpage>
            <pub-id pub-id-type="pmid">22851556</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2011.40.2719</pub-id>
          </element-citation>
        </ref>
        <ref id="bib13">
          <label>13</label>
          <element-citation publication-type="journal" id="sref13">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Wilhelm</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Smetak</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Reimer</surname>
                <given-names>P</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation</article-title>
            <source>Blood Cancer J</source>
            <volume>6</volume>
            <issue>7</issue>
            <year>2016</year>
            <fpage>e452</fpage>
            <pub-id pub-id-type="pmid">27471868</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bcj.2016.63</pub-id>
            <pub-id pub-id-type="pmcid">PMC5030384</pub-id>
          </element-citation>
        </ref>
        <ref id="bib14">
          <label>14</label>
          <element-citation publication-type="journal" id="sref14">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Park</surname>
                <given-names>SI</given-names>
              </name>
              <name name-style="western">
                <surname>Horwitz</surname>
                <given-names>SM</given-names>
              </name>
              <name name-style="western">
                <surname>Foss</surname>
                <given-names>FM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study</article-title>
            <source>Cancer</source>
            <volume>125</volume>
            <issue>9</issue>
            <year>2019</year>
            <fpage>1507</fpage>
            <lpage>1517</lpage>
            <pub-id pub-id-type="pmid">30694529</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.31861</pub-id>
            <pub-id pub-id-type="pmcid">PMC8269282</pub-id>
          </element-citation>
        </ref>
        <ref id="bib15">
          <label>15</label>
          <element-citation publication-type="journal" id="sref15">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Maura</surname>
                <given-names>F</given-names>
              </name>
              <name name-style="western">
                <surname>Dodero</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Carniti</surname>
                <given-names>C</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)</article-title>
            <source>Haematologica</source>
            <volume>106</volume>
            <issue>11</issue>
            <year>2021</year>
            <fpage>2918</fpage>
            <lpage>2926</lpage>
            <pub-id pub-id-type="pmid">33054126</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.3324/haematol.2020.262659</pub-id>
            <pub-id pub-id-type="pmcid">PMC8561277</pub-id>
          </element-citation>
        </ref>
        <ref id="bib16">
          <label>16</label>
          <element-citation publication-type="journal" id="sref16">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Lobello</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Tichy</surname>
                <given-names>B</given-names>
              </name>
              <name name-style="western">
                <surname>Bystry</surname>
                <given-names>V</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma</article-title>
            <source>Leukemia</source>
            <volume>35</volume>
            <issue>5</issue>
            <year>2021</year>
            <fpage>1500</fpage>
            <lpage>1505</lpage>
            <pub-id pub-id-type="pmid">33247178</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41375-020-01093-1</pub-id>
            <pub-id pub-id-type="pmcid">PMC8102183</pub-id>
          </element-citation>
        </ref>
        <ref id="bib17">
          <label>17</label>
          <element-citation publication-type="journal" id="sref17">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Laginestra</surname>
                <given-names>MA</given-names>
              </name>
              <name name-style="western">
                <surname>Cascione</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Motta</surname>
                <given-names>G</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified</article-title>
            <source>Mod Pathol</source>
            <volume>33</volume>
            <issue>2</issue>
            <year>2020</year>
            <fpage>179</fpage>
            <lpage>187</lpage>
            <pub-id pub-id-type="pmid">31028364</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41379-019-0279-8</pub-id>
            <pub-id pub-id-type="pmcid">PMC6994417</pub-id>
          </element-citation>
        </ref>
        <ref id="bib18">
          <label>18</label>
          <element-citation publication-type="journal" id="sref18">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Watatani</surname>
                <given-names>Y</given-names>
              </name>
              <name name-style="western">
                <surname>Sato</surname>
                <given-names>Y</given-names>
              </name>
              <name name-style="western">
                <surname>Miyoshi</surname>
                <given-names>H</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling</article-title>
            <source>Leukemia</source>
            <volume>33</volume>
            <issue>12</issue>
            <year>2019</year>
            <fpage>2867</fpage>
            <lpage>2883</lpage>
            <pub-id pub-id-type="pmid">31092896</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41375-019-0473-1</pub-id>
          </element-citation>
        </ref>
        <ref id="bib19">
          <label>19</label>
          <element-citation publication-type="journal" id="sref19">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Heavican</surname>
                <given-names>TB</given-names>
              </name>
              <name name-style="western">
                <surname>Bouska</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma</article-title>
            <source>Blood</source>
            <volume>133</volume>
            <issue>15</issue>
            <year>2019</year>
            <fpage>1664</fpage>
            <lpage>1676</lpage>
            <pub-id pub-id-type="pmid">30782609</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2018-09-872549</pub-id>
            <pub-id pub-id-type="pmcid">PMC6460420</pub-id>
          </element-citation>
        </ref>
        <ref id="bib20">
          <label>20</label>
          <element-citation publication-type="journal" id="sref20">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Pedersen</surname>
                <given-names>MB</given-names>
              </name>
              <name name-style="western">
                <surname>Hamilton-Dutoit</surname>
                <given-names>SJ</given-names>
              </name>
              <name name-style="western">
                <surname>Bendix</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study</article-title>
            <source>Blood</source>
            <volume>130</volume>
            <issue>4</issue>
            <year>2017</year>
            <fpage>554</fpage>
            <lpage>557</lpage>
            <pub-id pub-id-type="pmid">28522440</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2016-12-755496</pub-id>
            <pub-id pub-id-type="pmcid">PMC5533203</pub-id>
          </element-citation>
        </ref>
        <ref id="bib21">
          <label>21</label>
          <element-citation publication-type="journal" id="sref21">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Rohr</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Guo</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Huo</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Recurrent activating mutations of CD28 in peripheral T-cell lymphomas</article-title>
            <source>Leukemia</source>
            <volume>30</volume>
            <issue>5</issue>
            <year>2016</year>
            <fpage>1062</fpage>
            <lpage>1070</lpage>
            <pub-id pub-id-type="pmid">26719098</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/leu.2015.357</pub-id>
            <pub-id pub-id-type="pmcid">PMC5688878</pub-id>
          </element-citation>
        </ref>
        <ref id="bib22">
          <label>22</label>
          <element-citation publication-type="journal" id="sref22">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gao</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Aksoy</surname>
                <given-names>BA</given-names>
              </name>
              <name name-style="western">
                <surname>Dogrusoz</surname>
                <given-names>U</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal</article-title>
            <source>Sci Signal</source>
            <volume>6</volume>
            <issue>269</issue>
            <year>2013</year>
            <fpage>pl1</fpage>
            <pub-id pub-id-type="pmid">23550210</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scisignal.2004088</pub-id>
            <pub-id pub-id-type="pmcid">PMC4160307</pub-id>
          </element-citation>
        </ref>
        <ref id="bib23">
          <label>23</label>
          <element-citation publication-type="journal" id="sref23">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cerami</surname>
                <given-names>E</given-names>
              </name>
              <name name-style="western">
                <surname>Gao</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Dogrusoz</surname>
                <given-names>U</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data</article-title>
            <source>Cancer Discov</source>
            <volume>2</volume>
            <issue>5</issue>
            <year>2012</year>
            <fpage>401</fpage>
            <lpage>404</lpage>
            <pub-id pub-id-type="pmid">22588877</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-12-0095</pub-id>
            <pub-id pub-id-type="pmcid">PMC3956037</pub-id>
          </element-citation>
        </ref>
        <ref id="bib24">
          <label>24</label>
          <element-citation publication-type="journal" id="sref24">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cheng</surname>
                <given-names>DT</given-names>
              </name>
              <name name-style="western">
                <surname>Mitchell</surname>
                <given-names>TN</given-names>
              </name>
              <name name-style="western">
                <surname>Zehir</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology</article-title>
            <source>JÂ Mol Diagn</source>
            <volume>17</volume>
            <issue>3</issue>
            <year>2015</year>
            <fpage>251</fpage>
            <lpage>264</lpage>
            <pub-id pub-id-type="pmid">25801821</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jmoldx.2014.12.006</pub-id>
            <pub-id pub-id-type="pmcid">PMC5808190</pub-id>
          </element-citation>
        </ref>
        <ref id="bib25">
          <label>25</label>
          <element-citation publication-type="journal" id="sref25">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Zehir</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Benayed</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Shah</surname>
                <given-names>RH</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients</article-title>
            <source>Nat Med</source>
            <volume>23</volume>
            <issue>6</issue>
            <year>2017</year>
            <fpage>703</fpage>
            <lpage>713</lpage>
            <pub-id pub-id-type="pmid">28481359</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.4333</pub-id>
            <pub-id pub-id-type="pmcid">PMC5461196</pub-id>
          </element-citation>
        </ref>
        <ref id="bib26">
          <label>26</label>
          <element-citation publication-type="journal" id="sref26">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ellin</surname>
                <given-names>F</given-names>
              </name>
              <name name-style="western">
                <surname>Maurer</surname>
                <given-names>MJ</given-names>
              </name>
              <name name-style="western">
                <surname>Srour</surname>
                <given-names>L</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas</article-title>
            <source>Br J Haematol</source>
            <volume>186</volume>
            <issue>3</issue>
            <year>2019</year>
            <fpage>e24</fpage>
            <lpage>e27</lpage>
            <pub-id pub-id-type="pmid">30859549</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjh.15859</pub-id>
            <pub-id pub-id-type="pmcid">PMC7046310</pub-id>
          </element-citation>
        </ref>
        <ref id="bib27">
          <label>27</label>
          <element-citation publication-type="journal" id="sref27">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gallamini</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Stelitano</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Calvi</surname>
                <given-names>R</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study</article-title>
            <source>Blood</source>
            <volume>103</volume>
            <issue>7</issue>
            <year>2004</year>
            <fpage>2474</fpage>
            <lpage>2479</lpage>
            <pub-id pub-id-type="pmid">14645001</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2003-09-3080</pub-id>
          </element-citation>
        </ref>
        <ref id="bib28">
          <label>28</label>
          <element-citation publication-type="journal" id="sref28">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Weisenburger</surname>
                <given-names>DD</given-names>
              </name>
              <name name-style="western">
                <surname>Savage</surname>
                <given-names>KJ</given-names>
              </name>
              <name name-style="western">
                <surname>Harris</surname>
                <given-names>NL</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project</article-title>
            <source>Blood</source>
            <volume>117</volume>
            <issue>12</issue>
            <year>2011</year>
            <fpage>3402</fpage>
            <lpage>3408</lpage>
            <pub-id pub-id-type="pmid">21270441</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2010-09-310342</pub-id>
          </element-citation>
        </ref>
        <ref id="bib29">
          <label>29</label>
          <element-citation publication-type="journal" id="sref29">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Odejide</surname>
                <given-names>O</given-names>
              </name>
              <name name-style="western">
                <surname>Weigert</surname>
                <given-names>O</given-names>
              </name>
              <name name-style="western">
                <surname>Lane</surname>
                <given-names>AA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>AÂ targeted mutational landscape of angioimmunoblastic T-cell lymphoma</article-title>
            <source>Blood</source>
            <volume>123</volume>
            <issue>9</issue>
            <year>2014</year>
            <fpage>1293</fpage>
            <lpage>1296</lpage>
            <pub-id pub-id-type="pmid">24345752</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2013-10-531509</pub-id>
            <pub-id pub-id-type="pmcid">PMC4260974</pub-id>
          </element-citation>
        </ref>
        <ref id="bib30">
          <label>30</label>
          <element-citation publication-type="journal" id="sref30">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Chakravarty</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Gao</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Phillips</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>OncoKB: a precision oncology knowledge base</article-title>
            <source>JCO Precis Oncol</source>
            <volume>2017</volume>
            <year>2017</year>
            <fpage>1</fpage>
            <lpage>16</lpage>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/PO.17.00011</pub-id>
            <pub-id pub-id-type="pmcid">PMC5586540</pub-id>
            <pub-id pub-id-type="pmid">28890946</pub-id>
          </element-citation>
        </ref>
        <ref id="bib31">
          <label>31</label>
          <element-citation publication-type="journal" id="sref31">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gao</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Chang</surname>
                <given-names>MT</given-names>
              </name>
              <name name-style="western">
                <surname>Johnsen</surname>
                <given-names>HC</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets</article-title>
            <source>Genome Med</source>
            <volume>9</volume>
            <issue>1</issue>
            <year>2017</year>
            <fpage>4</fpage>
            <pub-id pub-id-type="pmid">28115009</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-016-0393-x</pub-id>
            <pub-id pub-id-type="pmcid">PMC5260099</pub-id>
          </element-citation>
        </ref>
        <ref id="bib32">
          <label>32</label>
          <element-citation publication-type="journal" id="sref32">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Eskelund</surname>
                <given-names>CW</given-names>
              </name>
              <name name-style="western">
                <surname>Dahl</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Hansen</surname>
                <given-names>JW</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy</article-title>
            <source>Blood</source>
            <volume>130</volume>
            <issue>17</issue>
            <year>2017</year>
            <fpage>1903</fpage>
            <lpage>1910</lpage>
            <pub-id pub-id-type="pmid">28819011</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2017-04-779736</pub-id>
          </element-citation>
        </ref>
        <ref id="bib33">
          <label>33</label>
          <element-citation publication-type="journal" id="sref33">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Malcikova</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Pavlova</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Kunt Vonkova</surname>
                <given-names>B</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options</article-title>
            <source>Blood</source>
            <volume>138</volume>
            <issue>25</issue>
            <year>2021</year>
            <fpage>2670</fpage>
            <lpage>2685</lpage>
            <pub-id pub-id-type="pmid">33945616</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood.2020009530</pub-id>
            <pub-id pub-id-type="pmcid">PMC8703362</pub-id>
          </element-citation>
        </ref>
        <ref id="bib34">
          <label>34</label>
          <element-citation publication-type="journal" id="sref34">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Molica</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Mazzone</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Niscola</surname>
                <given-names>P</given-names>
              </name>
              <name name-style="western">
                <surname>de Fabritiis</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>TP53 mutations in acute myeloid leukemia: still a daunting challenge?</article-title>
            <source>Front Oncol</source>
            <volume>10</volume>
            <year>2020</year>
            <fpage>610820</fpage>
            <pub-id pub-id-type="pmid">33628731</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2020.610820</pub-id>
            <pub-id pub-id-type="pmcid">PMC7897660</pub-id>
          </element-citation>
        </ref>
        <ref id="bib35">
          <label>35</label>
          <element-citation publication-type="journal" id="sref35">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Martello</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Poletti</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Borsi</surname>
                <given-names>E</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma</article-title>
            <source>Blood Cancer J</source>
            <volume>12</volume>
            <issue>1</issue>
            <year>2022</year>
            <fpage>15</fpage>
            <pub-id pub-id-type="pmid">35082295</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41408-022-00610-y</pub-id>
            <pub-id pub-id-type="pmcid">PMC8791929</pub-id>
          </element-citation>
        </ref>
        <ref id="bib36">
          <label>36</label>
          <element-citation publication-type="journal" id="sref36">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Intlekofer</surname>
                <given-names>AM</given-names>
              </name>
              <name name-style="western">
                <surname>Joffe</surname>
                <given-names>E</given-names>
              </name>
              <name name-style="western">
                <surname>Batlevi</surname>
                <given-names>CL</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay</article-title>
            <source>Blood Cancer J</source>
            <volume>8</volume>
            <issue>6</issue>
            <year>2018</year>
            <fpage>60</fpage>
            <pub-id pub-id-type="pmid">29895903</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41408-018-0089-0</pub-id>
            <pub-id pub-id-type="pmcid">PMC5997645</pub-id>
          </element-citation>
        </ref>
        <ref id="bib37">
          <label>37</label>
          <element-citation publication-type="journal" id="sref37">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>RodrÃ­guez</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Alonso-Alonso</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>TomÃ¡s-Roca</surname>
                <given-names>L</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers</article-title>
            <source>Blood Adv</source>
            <volume>5</volume>
            <issue>24</issue>
            <year>2021</year>
            <fpage>5588</fpage>
            <lpage>5598</lpage>
            <pub-id pub-id-type="pmid">34592752</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/bloodadvances.2021005171</pub-id>
            <pub-id pub-id-type="pmcid">PMC8714715</pub-id>
          </element-citation>
        </ref>
        <ref id="bib38">
          <label>38</label>
          <element-citation publication-type="journal" id="sref38">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Yoon</surname>
                <given-names>SE</given-names>
              </name>
              <name name-style="western">
                <surname>Cho</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Kim</surname>
                <given-names>YJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas</article-title>
            <source>Exp Hematol Oncol</source>
            <volume>10</volume>
            <issue>1</issue>
            <year>2021</year>
            <fpage>33</fpage>
            <pub-id pub-id-type="pmid">33990228</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40164-021-00224-3</pub-id>
            <pub-id pub-id-type="pmcid">PMC8120779</pub-id>
          </element-citation>
        </ref>
        <ref id="bib39">
          <label>39</label>
          <element-citation publication-type="journal" id="sref39">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Roberti</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Dobay</surname>
                <given-names>MP</given-names>
              </name>
              <name name-style="western">
                <surname>Bisig</surname>
                <given-names>B</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations</article-title>
            <source>Nat Commun</source>
            <volume>7</volume>
            <year>2016</year>
            <fpage>12602</fpage>
            <pub-id pub-id-type="pmid">27600764</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms12602</pub-id>
            <pub-id pub-id-type="pmcid">PMC5023950</pub-id>
          </element-citation>
        </ref>
        <ref id="bib40">
          <label>40</label>
          <element-citation publication-type="journal" id="sref40">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Horwitz</surname>
                <given-names>SM</given-names>
              </name>
              <name name-style="western">
                <surname>Moskowitz</surname>
                <given-names>AJ</given-names>
              </name>
              <name name-style="western">
                <surname>Mehta-Shah</surname>
                <given-names>N</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The combination of duvelisib and romidepsin (Dr) is highly active against relapsed/refractory peripheral T-cell lymphoma with low rates of transaminitis: final results</article-title>
            <source>Hematol Oncol</source>
            <volume>39</volume>
            <issue>suppl 2</issue>
            <year>2021</year>
          </element-citation>
        </ref>
        <ref id="bib41">
          <label>41</label>
          <element-citation publication-type="journal" id="sref41">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ishitsuka</surname>
                <given-names>K</given-names>
              </name>
              <name name-style="western">
                <surname>Izutsu</surname>
                <given-names>K</given-names>
              </name>
              <name name-style="western">
                <surname>Maruyama</surname>
                <given-names>D</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>First-in-human study of the Ezh1 and Ezh2 dual inhibitor valemetostat tosylate (Ds-3201b) in patients with relapsed or refractory non-Hodgkin lymphomas</article-title>
            <source>Hematol Oncol</source>
            <volume>39</volume>
            <issue>suppl 2</issue>
            <year>2021</year>
          </element-citation>
        </ref>
        <ref id="bib42">
          <label>42</label>
          <element-citation publication-type="journal" id="sref42">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Brammer</surname>
                <given-names>JE</given-names>
              </name>
              <name name-style="western">
                <surname>Zinzani</surname>
                <given-names>PL</given-names>
              </name>
              <name name-style="western">
                <surname>Zain</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma from the phase 2 primo trial: results of an interim analysis</article-title>
            <source>Blood</source>
            <volume>138</volume>
            <issue>suppl 1</issue>
            <year>2021</year>
            <object-id pub-id-type="publisher-id">2456-2456</object-id>
          </element-citation>
        </ref>
        <ref id="bib43">
          <label>43</label>
          <element-citation publication-type="journal" id="sref43">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Moskowitz</surname>
                <given-names>AJ</given-names>
              </name>
              <name name-style="western">
                <surname>Ghione</surname>
                <given-names>P</given-names>
              </name>
              <name name-style="western">
                <surname>Jacobsen</surname>
                <given-names>E</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>AÂ phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas</article-title>
            <source>Blood</source>
            <volume>138</volume>
            <issue>26</issue>
            <year>2021</year>
            <fpage>2828</fpage>
            <lpage>2837</lpage>
            <pub-id pub-id-type="pmid">34653242</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood.2021013379</pub-id>
            <pub-id pub-id-type="pmcid">PMC8718625</pub-id>
          </element-citation>
        </ref>
        <ref id="bib44">
          <label>44</label>
          <element-citation publication-type="journal" id="sref44">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Horwitz</surname>
                <given-names>SM</given-names>
              </name>
              <name name-style="western">
                <surname>Feldman</surname>
                <given-names>TA</given-names>
              </name>
              <name name-style="western">
                <surname>Hess</surname>
                <given-names>BT</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>AÂ phase 2 study of the dual SYK/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma</article-title>
            <source>Blood</source>
            <volume>134</volume>
            <issue>suppl 1</issue>
            <year>2019</year>
            <object-id pub-id-type="publisher-id">466-466</object-id>
          </element-citation>
        </ref>
        <ref id="bib45">
          <label>45</label>
          <element-citation publication-type="journal" id="sref45">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Wang</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Feldman</surname>
                <given-names>AL</given-names>
              </name>
              <name name-style="western">
                <surname>Wada</surname>
                <given-names>DA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features</article-title>
            <source>Blood</source>
            <volume>123</volume>
            <issue>19</issue>
            <year>2014</year>
            <fpage>3007</fpage>
            <lpage>3015</lpage>
            <pub-id pub-id-type="pmid">24497534</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2013-12-544809</pub-id>
            <pub-id pub-id-type="pmcid">PMC4014843</pub-id>
          </element-citation>
        </ref>
      </ref-list>
      <sec id="appsec1" sec-type="supplementary-material">
        <title>Supplementary Material</title>
        <p id="p0275">
<supplementary-material content-type="local-data" id="ec1" position="float" orientation="portrait"><caption><title>Supplemental File 1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="BLOODA_ADV-2023-009953-mmc1.xlsx" position="float" orientation="portrait"/></supplementary-material>
<supplementary-material content-type="local-data" id="ec2" position="float" orientation="portrait"><caption><title>Supplemental TablesÂ and Figures</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="BLOODA_ADV-2023-009953-mmc2.pdf" position="float" orientation="portrait"/></supplementary-material>
</p>
      </sec>
      <ack id="ack0010">
        <title>Acknowledgments</title>
        <p id="p0255">Editorial support was provided by Katharine Olla Inoue and Clare Wilhelm at Memorial Sloan Kettering Cancer Center.</p>
        <p id="p0260">This work was supported in part by <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source>/<funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source> grant P30 CA00878, the Leukemia and Lymphoma Society (7026-21), and the Nonnaâ€™s Garden Foundation.</p>
        <sec id="sec5">
          <title>Authorship</title>
          <p id="p0265">Contributions: W.T.J. designed the research study, collected the data, and wrote the manuscript; N. Ganesan performed the primary statistical analysis; Z.D.E.-P., A.J.M., and R.N.S. reviewed and assisted in the writing of the manuscript; C.R.M. collected the data; N. Galasso collected the data and assisted in the institutional review board submission process; T.C. collected the data; N.K. reviewed and assisted in the writing of the manuscript; U.A. reviewed the sequencing data, and reviewed and assisted in the writing of the manuscript; N.E.L. reviewed the pathology diagnoses; A.D.Z., M.L.P., M.J.M., A.N., A.M.H., P.H., P.C.C., D.J.S., A.M.I., C.L.B., A.K., C.N.O., C.S.S., L.F., J.K.L., S.A.V., and G.S. reviewed and assisted in the writing of the manuscript; A.D. reviewed the pathology diagnoses; N.D.S. assisted with data review from cBioPortal; M.E.A. reviewed the clinically reported genetic sequencing results; and S.M.H. provided oversight to the research study design and reviewed and assisted in writing the manuscript.</p>
        </sec>
      </ack>
      <fn-group>
        <fn id="d35e2654">
          <p id="ntpara0010">Genetic data are available at the cBioPortal for Cancer Genomics at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cbioportal.org/study/summary?id=mtnn_msk_2022" id="intref0010">https://www.cbioportal.org/study/summary?id=mtnn_msk_2022</ext-link>.</p>
        </fn>
        <fn id="d35e2660">
          <p id="ntpara0015">Deidentified data that are not publicly accessible or included in this article or data supplement are available upon request from the corresponding author, William T. Johnson (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="mailto:johnsow3@mskcc.org" id="intref0015">johnsow3@mskcc.org</ext-link>).</p>
        </fn>
        <fn id="d35e2666">
          <p id="ntpara0020">The full-text version of this article contains a data supplement.</p>
        </fn>
      </fn-group>
    </back>
  </article>
</pmc-articleset>
